Page last updated: 2024-12-06

etomidate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Etomidate is a short-acting non-barbiturate intravenous anesthetic that is commonly used for induction of anesthesia. It is synthesized through a series of chemical reactions involving the starting materials ethyl chloroacetate and 2,4-dichlorophenoxyacetaldehyde. Etomidate exhibits a rapid onset of action and a short duration of action, making it suitable for rapid induction and recovery. It primarily acts by potentiating the inhibitory effects of the neurotransmitter GABA in the brain. Etomidate is known to have a minimal effect on cardiovascular and respiratory function, making it a preferred choice for patients with compromised cardiovascular status. However, it can suppress adrenal steroid synthesis, leading to potential complications in patients with adrenal insufficiency. Etomidate is extensively studied due to its rapid onset of action, short duration, and minimal cardiovascular effects. Researchers are investigating its potential role in various clinical settings, including emergency procedures, critical care medicine, and neurocritical care. The impact of etomidate on adrenal steroid synthesis and its potential adverse effects continue to be areas of ongoing research.'

ethnor: an adsorbable haemostatic bone sealant [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID36339
CHEMBL ID23731
CHEBI ID91759
SCHEMBL ID39485
MeSH IDM0007928
PubMed CID667484
CHEMBL ID681
CHEBI ID4910
SCHEMBL ID39487
MeSH IDM0007928

Synonyms (193)

Synonym
HMS3393P18
1h-imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (r)-
smr000010931
amidate
ethyl 1-(1-phenylethyl)-1h-imidazole-5-carboxylate
c14h16n2o2
PRESTWICK2_001041
NCGC00016817-01
cas-33125-97-2
absele
MLS000034952 ,
PRESTWICK1_001041
PRESTWICK0_001041
SPBIO_002901
MLS001240191
HMS2093P17
AC-5898
CHEMBL23731
ethyl 3-(1-phenylethyl)imidazole-4-carboxylate
HMS1612G10
AKOS000548952
HMS1571A04
cpd000010931
HMS3259F15
15301-65-2
EN300-50290
A821630
nsc759160
pharmakon1600-01505599
dtxcid403033
tox21_110628
HMS2235K14
ethnor
1h-imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (+-)-
FT-0630568
S1329
HMS3369P19
HMS3371K15
(+)-ethyl 1-(.alpha.-methylbenzyl)imidazole-5-carboxylate
imidazole-5-carboxylic acid, 1-(.alpha.-methylbenzyl)-, ethyl ester, (r)-(+)-
AKOS021628930
NC00657
SCHEMBL39485
NCGC00025176-02
tox21_110628_1
AB00439988-11
(-)-ethyl 1-(1-phenylethyl)-1h-imidazole-5-carboxylate
r-(+) ethyl 1-(1-phenylethyl)-1h-imidazole-5-carboxylate
(-)-ethyl 1-(1-phenylethyl)-1h-imidazole- 5-carboxylate
ethyl 1-(1-phenylethyl)-1h-imidazole-5-carboxylate, (+)-
1h-imidazole-5-carboxylic acid, 1-(.alpha.-methylbenzyl)-, ethyl ester, (+)-
1-(.alpha.-methylbenzyl)-1h-imidazole-5-carboxylic acid ethyl ester
(r)-(+)-1-(.alpha.-methylbenzyl)imidazole-5-carboxylic acid ethyl ester
MLS006011948
HB0937
HMS3428L14
OPERA_ID_1830
AB00439988_13
sr-01000325781
SR-01000325781-1
CHEBI:91759
HMS3654N15
SR-01000325781-5
SR-01000325781-3
SBI-0206822.P001
NCGC00036076-03
bdbm238149
us9394290, eto (etomidate)
(+/-)-etomidate
SW197275-2
s-(-)-etomidate
r 16659 pound>>r-16659 pound>>r16659 pound>>r 26490 pound>>r-26490 pound>>r26490
BCP21365
3-(1-phenylethyl)-4-imidazolecarboxylic acid ethyl ester
Q27163565
DS-14867
BRD-A54880345-001-11-8
CCG-266910
ethyl 3-(1-phenylethyl)imidazole-4-carboxylate.
CS-0081287
ethyl1-(1-phenylethyl)-1h-imidazole-5-carboxylate
rac-etomidate
DTXSID101347652
HMS3267N06
hypnomidate
r-16659
brn 0665833
1-(1-phenylethyl)-1h-imidazole-5-carboxylic acid ethyl ester
1h-imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (+)-
1-(alpha-methylbenzyl)-1h-imidazole-5-carboxylic acid ethyl ester
(d)-etomidate
r 16659
d-etomidate
1h-imidazole-5-carboxylic acid, 1-((1r)-1-phenylethyl)-, ethyl ester
amidate (pharmaceutical)
einecs 251-385-9
etomidato [inn-spanish]
imidazole-5-carboxylic acid, 1-(alpha-methylbenzyl)-, ethyl ester, (r)-(+)-
etomidatum [inn-latin]
ethomidate
radenarcon
NCGC00025176-01
MLS001424163
1-(1-phenylethyl)-imidazole-5-carboxylic acid, ethyl ester
C07522
etomidate
33125-97-2
etomidate, >98% (hplc), powder
smr000466277
MLS000758268
1h-imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (r)- [cas]
(+)-etomidate
r-(+)-ethyl 1-(1-phenylethyl)-1h-imidazole-5-carboxylate
DB00292
(+)-ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate
3-((r)-1-phenyl-ethyl)-3h-imidazole-4-carboxylic acid ethyl ester
(r)-(+)-1-(alpha-methylbenzyl)imidazole-5-carboxylic acid ethyl ester
(r)-1-(1-phenylethyl)-1h-imidazole-5-carboxylic acid ethyl ester
etomidate (usp/inn)
amidate (tn)
D00548
HMS2051P18
nsc-759160
CHEMBL681 ,
etomidatum
etomidato
CHEBI:4910 ,
ethyl 1-[(1r)-1-phenylethyl]-1h-imidazole-5-carboxylate
r-etomidate
r(+)-etomidate
(r)-1-(1-phenylethyl)-1h-imidazole-5-carboxylicacid ethyl ester
bdbm50125935
ethyl 3-[(1r)-1-phenylethyl]imidazole-4-carboxylate
ethyl (r)-(+)-1-(1-phenylethyl)-1h-imidazole-5-carboxylate
(r)-(+)-1-(1-phenylethyl)-1h-imidazole-5-carboxylic acid ethyl ester
E0897
ethyl (r)-1-(1-phenylethyl)-1h-imidazole-5-carboxylate
dtxsid5023033 ,
etomidic acid
AKOS015920052
HMS2232A08
AM803710
CCG-101054
nsc 759160
unii-z22628b598
z22628b598 ,
etomidate [usan:usp:inn:ban]
gtpl5463
etomidate [inn]
etomidate [usan]
etomidate [who-dd]
etomidate [ep monograph]
etomidate [mart.]
etomidate [usp monograph]
etomidate [usp-rs]
etomidate [mi]
etomidate [orange book]
etomidate [vandf]
CS-1833
HY-B0100
(r)-ethyl 1-(1-phenylethyl)-1h-imidazole-5-carboxylate
NC00304
SCHEMBL39487
r-(+)-ethyl-1-(1-phenylethyl)-1h-imidazole-5-carboxylate
Q-201102
1h-imidazole-5-carboxylic acid, 1-[(1r)-1-phenylethyl]-, ethyl ester
AB00639951_06
mfcd00869295
SR-01000597569-1
sr-01000597569
GS-3208
etomidate, united states pharmacopeia (usp) reference standard
etomidate, european pharmacopoeia (ep) reference standard
etomidate 1.0 mg/ml in methanol
etomidate 0.1 mg/ml in methanol
Q418445
Z1741976844
HMS3676D11
V8D ,
HMS3412D11
BRD-K55055802-001-10-2
EN300-1074318
etomidate (ep monograph)
n01ax07
ethyl 1-((1r)-1-phenylethyl)-1h-imidazole-5-carboxylate
etomidate (usp-rs)
etomidate (mart.)
etomidate (usan:usp:inn:ban)
etomidatum (inn-latin)
etomidato (inn-spanish)
etomidate injection
amidate(tm) etomidate
etomidate (usp monograph)

Research Excerpts

Toxicity

To determine the frequency, severity and duration of adverse events including myoclonus, pain on injection, hypersalivation, regurgitation and apnoea after administration of midazolam or saline followed by etomidate in hydromorphone premedicated dogs.

ExcerptReferenceRelevance
" We believed that this represented an adverse effect that was probably related to the study drug and the study was stopped."( Propylene glycol toxicity following continuous etomidate infusion for the control of refractory cerebral edema.
Aranda, M; Giannotta, SL; Levy, ML; Zelman, V, 1995
)
0.29
" Adverse effects of propylene glycol were observed including hyperosmolality with an increased osmolal gap, hemolysis, hemoglobinuria, and metabolic acidosis."( Propylene glycol toxicity caused by prolonged infusion of etomidate.
Martin, N; Peacock, W; Rubinstein, E; Van de Wiele, B, 1995
)
0.29
" The aim of this study was to compare clinical efficacy, tolerability and adverse effects of thiopental, etomidate and propofol."( [Adverse effects reported after inductive doses of the intravenous anesthetics, thiopentone, etomidate and propofol].
Adamov, A; Djordjević, B; Krivokapić, D; Loncar-Stojiljković, D; Stojiljković, MP,
)
0.13
"Neurotoxicity is the dose-limiting side-effect of vincristine in cancer therapy."( Effect of thiopental, propofol, and etomidate on vincristine toxicity in PC12 cells.
Chen, JT; Cheng, JT; Chou, AK; Lee, TC; Lin, CR; Lin, FC; Yang, LC, 2002
)
0.31
" The data reproduce our previous observation that, relative to a halothane-anesthetized control state, etomidate has an adverse effect on ischemic injury in the setting of temporary focal cerebral ischemia."( The role of nitric oxide synthase inhibition in the adverse effects of etomidate in the setting of focal cerebral ischemia in rats.
Cole, DJ; Drummond, JC; McKay, LD; Patel, PM, 2005
)
0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" The adverse event (AE) rate was 18% and included apnea (10%), inadequate sedation (3%), bradycardia (2%), desaturation (1%), hypotension (1%) and bag-valve-mask use (1%)."( Emergency department procedural sedation and analgesia: A Canadian Community Effectiveness and Safety Study (ACCESS).
Mensour, M; Michaud, J; Pineau, R; Sahai, V, 2006
)
0.33
"Procedural sedation was safe and effective in our environment."( Emergency department procedural sedation and analgesia: A Canadian Community Effectiveness and Safety Study (ACCESS).
Mensour, M; Michaud, J; Pineau, R; Sahai, V, 2006
)
0.33
"The results of this study suggest that (a) etomidate is much safer than propofol for first-trimester surgical abortions and (b) using a lower dose of etomidate, supplemented with fentanyl and midazolam, is more beneficial than the use of etomidate with or without fentanyl in reducing adverse effects like myoclonus and postoperative nausea and vomiting."( A comparison of anesthetic regimens using etomidate and propofol in patients undergoing first-trimester abortions: double-blind, randomized clinical trial of safety and efficacy.
Chu, S; Deng, F; Wu, J; Wu, Z; Xia, G; Yao, S, 2013
)
0.39
" This included the electroencephalographic and motor effects of etomidate injection and their time course (onset and recovery), Wada test results (language laterality and memory performance), and all adverse events during the procedure."( Intracarotid etomidate is a safe alternative to sodium amobarbital for the Wada test.
Cohn, M; Manninen, P; Mariappan, R; McAndrews, MP; Tai, P; Valiante, T; Venkatraghavan, L, 2013
)
0.39
"From our experience, etomidate is a safe alternative to sodium amobarbital for the Wada test for determining the hemispheric dominance for speech and in predicting the memory outcome."( Intracarotid etomidate is a safe alternative to sodium amobarbital for the Wada test.
Cohn, M; Manninen, P; Mariappan, R; McAndrews, MP; Tai, P; Valiante, T; Venkatraghavan, L, 2013
)
0.39
" This meta-analysis suggests that pretreatment with opioids before injecting etomidate was effective for preventing etomidate-induced myoclonus and can reduce the intensity of myoclonus without any adverse effects."( Efficacy and Safety of Opioids for the Prevention of Etomidate-Induced Myoclonus: A Meta-Analysis.
Kang, JL; Li, QB; Wang, BN; Wang, J; Wu, YY; Xu, XW,
)
0.13
" Safety was assessed by clinical laboratory evaluations, infusion-site reactions, continuous monitoring of vital signs, physical examination, adverse event monitoring, and adrenocorticotropic hormone stimulation testing."( A Phase 1, Single-center, Double-blind, Placebo-controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Clinical Effects, and Pharmacokinetics-Pharmacodynamics of Intravenous Cyclopropyl-methoxycarbonylmetomidate (ABP-700) after a Single
Absalom, AR; Campagna, JA; Chou, T; den Daas, I; Eleveld, DJ; Meier, S; Meyer, P; Struys, MMRF; Sweeney, SP; Valk, BI; van Amsterdam, K, 2017
)
0.46
" No serious adverse events were reported."( A Phase 1, Single-center, Double-blind, Placebo-controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Clinical Effects, and Pharmacokinetics-Pharmacodynamics of Intravenous Cyclopropyl-methoxycarbonylmetomidate (ABP-700) after a Single
Absalom, AR; Campagna, JA; Chou, T; den Daas, I; Eleveld, DJ; Meier, S; Meyer, P; Struys, MMRF; Sweeney, SP; Valk, BI; van Amsterdam, K, 2017
)
0.46
"Recent studies have shown that etomidate is associated with fewer serious adverse events than propofol and has a noninferior sedative effect."( Efficacy and safety of etomidate-midazolam for screening colonoscopy in the elderly: A prospective double-blinded randomized controlled study.
Choi, HS; Choi, SJ; Chun, HJ; Jeen, YT; Keum, B; Kim, CD; Kim, ES; Kim, SH; Kim, W; Lee, BJ; Lee, HS; Lee, JM; Min, G; Park, JJ, 2018
)
0.48
" The primary outcome was all cardiopulmonary adverse events."( Efficacy and safety of etomidate-midazolam for screening colonoscopy in the elderly: A prospective double-blinded randomized controlled study.
Choi, HS; Choi, SJ; Chun, HJ; Jeen, YT; Keum, B; Kim, CD; Kim, ES; Kim, SH; Kim, W; Lee, BJ; Lee, HS; Lee, JM; Min, G; Park, JJ, 2018
)
0.48
"The incidence of cardiopulmonary adverse events was higher in the propofol group (72."( Efficacy and safety of etomidate-midazolam for screening colonoscopy in the elderly: A prospective double-blinded randomized controlled study.
Choi, HS; Choi, SJ; Chun, HJ; Jeen, YT; Keum, B; Kim, CD; Kim, ES; Kim, SH; Kim, W; Lee, BJ; Lee, HS; Lee, JM; Min, G; Park, JJ, 2018
)
0.48
" The combined use of propofol and etomidate can improve and produce an apparent beneficial effect on the adverse effects of propofol or etomidate alone, and it was safer and more effective than propofol or etomidate alone."( Safety and efficacy of combined use of propofol and etomidate for sedation during gastroscopy: Systematic review and meta-analysis.
Chen, L; Jiang, J; Li, Y; Liang, X; Tan, X; Wen, H, 2019
)
0.51
"The EST was found to be successful and safe in lateralizing language in most of our drug refractory pediatric epilepsy cohort."( Reliability and safety of Etomidate speech test in children with drug resistant focal epilepsy.
Carter Snead, O; Go, C; Gulati, P; Jain, P; Kerr, E; Lou Smith, M; Muthusami, P; Shroff, M; Whitney, R, 2019
)
0.51
" In the present study, we measured the potential adverse effects of ET-26HCl in beagle dogs in accordance with the Guidance on single- and repeated-dose toxicity published by the China Food and Drug Administration."( Preclinical safety evaluation of ET-26 hydrochloride, a novel intravenous anesthetic agent, in beagle dogs.
Deng, C; Gong, D; Kang, Y; Liu, J; Zhang, W; Zhang, Y, 2020
)
0.56
" The objective of this study was to evaluate the potential adverse effects of ET-26HCl in rats."( Non-clinical single- and repeated-dose toxicity studies of ET-26 hydrochloride in rats.
Deng, C; Gong, D; Kang, Y; Liu, J; Zhang, W; Zhang, Y, 2020
)
0.56
"To determine the frequency, severity and duration of adverse events including myoclonus, pain on injection, hypersalivation, regurgitation and apnoea after administration of midazolam or saline followed by etomidate in hydromorphone premedicated dogs."( Descriptive assessment of adverse events associated with midazolam-etomidate versus saline-etomidate in healthy hydromorphone premedicated dogs.
Calbay, R; da Cunha, AF; Hofmeister, EH; Jones, TL, 2021
)
0.62
" Further investigation is needed to determine if midazolam reduced the incidence of adverse events or improved the induction quality when combined with hydromorphone and etomidate."( Descriptive assessment of adverse events associated with midazolam-etomidate versus saline-etomidate in healthy hydromorphone premedicated dogs.
Calbay, R; da Cunha, AF; Hofmeister, EH; Jones, TL, 2021
)
0.62
" Demographics, sedatives, and analgesia associations with adverse events were explored with logistic regressions."( Fifteen Years' Experience With Safe and Effective Procedural Sedation in Infants and Children in a General Emergency Department.
Mace, SE; Nowacki, AS; Peterson, B; Ulintz, A; Worley, J; Zamborsky, S, 2021
)
0.62
"3%) resulted in a side effect and 8 PS (3."( Fifteen Years' Experience With Safe and Effective Procedural Sedation in Infants and Children in a General Emergency Department.
Mace, SE; Nowacki, AS; Peterson, B; Ulintz, A; Worley, J; Zamborsky, S, 2021
)
0.62
" Secondary endpoints included time metrics, hemodynamics, consumption of fentanyl, etomidate, propofol, and remimazolam, intraoperative body movement, patient and endoscopist satisfaction scores, supplemental dose of sedative and fentanyl, and incidence and severity of adverse events."( The Efficacy and Safety of Remimazolam Tosilate versus Etomidate-Propofol in Elderly Outpatients Undergoing Colonoscopy: A Prospective, Randomized, Single-Blind, Non-Inferiority Trial.
Ding, B; Liu, L; Liu, X; Sha, Y; Shi, F; Zhang, Y; Zhao, T, 2021
)
0.62
" However, the effect of pretreatment with oxycodone on recovery of cognitive function and adverse effects has rarely been studied."( Safety and efficacy of etomidate in combination with oxycodone in painless gastroscopic procedures in the elderly: A prospective randomized controlled trial study.
Li, YP; Zhou, Y, 2023
)
0.91
" Adverse events, including somatic motor reactions, hypotension, bradycardia, myocardial tremor, nausea and vomiting, and injection pain, were also recorded in both groups."( Safety and efficacy of etomidate in combination with oxycodone in painless gastroscopic procedures in the elderly: A prospective randomized controlled trial study.
Li, YP; Zhou, Y, 2023
)
0.91
" Fewer adverse events such as dynamic body reactions, cardiac tremor, nausea and vomiting, and injection pain occurred in the observation group than in the control group (P < ."( Safety and efficacy of etomidate in combination with oxycodone in painless gastroscopic procedures in the elderly: A prospective randomized controlled trial study.
Li, YP; Zhou, Y, 2023
)
0.91
"Etomidate in combination with oxycodone for painless gastroscopic operation in the elderly is a safe and effective anesthetic strategy."( Safety and efficacy of etomidate in combination with oxycodone in painless gastroscopic procedures in the elderly: A prospective randomized controlled trial study.
Li, YP; Zhou, Y, 2023
)
0.91
"Due to longer procedure duration and an unfavorable side effect profile, etomidate appears inferior to methohexital as an anesthetic agent in mECT despite longer seizure durations."( Comparison of etomidate and methohexital as anesthetic agents for continuation and maintenance electroconvulsive therapy: A retrospective analysis of seizure quality and safety.
Baldinger-Melich, P; Eder, V; Frey, R; Kress, HG; Michalek-Sauberer, A; Millischer, V; Pramhas, S; Rujescu, D; Wiedermann, I, 2023
)
0.91

Pharmacokinetics

The pharmacokinetic behaviour of etomidate was investigated in 7 patients. An increased hypnotic effect of the drug was observed during hypovolemia that is mainly attributed to pharmacokinetics.

ExcerptReferenceRelevance
" Plasma concentrations were fitted to a triexponential equation consistent with a three-compartment open pharmacokinetic model."( Pharmacokinetics of etomidate, a new intravenous anesthetic.
Ambre, JJ; Ghoneim, MM; Van Hamme, MJ, 1978
)
0.26
" The application of the design technique is illustrated in two typical situations: lacking a probability model for the pharmacokinetic parameters (etomidate) and having a probability model for the pharmacokinetic parameters (theophylline)."( Open-loop stochastic control of pharmacokinetic systems: a new method for design of dosing regimens.
Lago, PJ, 1992
)
0.28
" There were significant alterations in pharmacokinetic parameters in the cirrhotic patients."( [Pharmacokinetics of continuous infusion of etomidate in cirrhotic patients].
Bonnardot, JP; Brule, ML; Deligne, P; Deslauriers, M; Flaisler, B; Levron, JC, 1991
)
0.28
" Disposition of this carboxylated imidazole best conformed to a 2- (n = 2) and a 3- compartment (n = 4) open pharmacokinetic model."( Pharmacokinetics of etomidate in cats.
Benson, GJ; Davis, LE; Koritz, GD; Thurmon, JC; Tranquilli, WJ; Wertz, EM, 1990
)
0.28
" No age-related difference was found inside P group with regard to pharmacokinetic parameters."( [Comparison of the pharmacokinetics of etomidate in children and in adults].
Gaillard, JL; Le Mapihan, Y; Le Moing, JP; Levron, JC; Rosemblatt, JM; Sfez, M, 1990
)
0.28
" Fentanyl did not alter the elimination half-life of R 8110."( Hypnoanalgesia with R 8110/fentanyl in the dog: pharmacodynamic and pharmacokinetic interactions.
Degryse, AD; Heykants, J; Lagerweij, E; Michiels, M; Monbaliu, J; Ooms, LA; Van Dijk, P; Woestenborghs, R, 1988
)
0.27
" The kinetics of the analgesic can be described by a two-compartment model; the elimination half-life has a mean value of 64."( Pharmacokinetic data analysis of alfentanil after multiple injections and etomidate-infusion in patients undergoing orthopedic surgery.
Abel, J; Freye, E; Haag, W; Hartung, E; Klatte, A; Richter, O, 1985
)
0.27
" The drug input function, the pharmacokinetic parameters of etomidate as derived from a 'least squares' fit, and the median EEG frequency were used to establish a pharmacological model of etomidate."( Quantitation of the EEG and pharmacodynamic modelling of hypnotic drugs: etomidate as an example.
Schüttler, J; Schwilden, H; Stoeckel, H, 1985
)
0.27
" Pharmacokinetic analysis was undertaken using an open two-compartment model."( Infusion strategies to investigate the pharmacokinetics and pharmacodynamics of hypnotic drugs: etomidate as an example.
Schüttler, J; Schwilden, H; Stoeckel, H, 1985
)
0.27
" The decrease in the plasma concentration after discontinuing the infusion was consistent with a three-compartment pharmacokinetic model."( Pharmacokinetics of etomidate associated with prolonged i.v. infusion.
Edbrooke, DL; Hebron, BS; Mather, SJ; Newby, DM, 1983
)
0.27
" The postinfusion plasma etomidate concentration was described by a three compartment model with a mean half-life of 540 minutes (SEM 66."( Etomidate anaesthesia in patients with cirrhosis of the liver: pharmacokinetic data.
Manger, FW; van Beem, H; van Bentem, N; van Boxtel, C, 1983
)
0.27
"The pharmacokinetic behaviour of etomidate was investigated in 7 patients."( [Pharmacokinetics of etomidate in man (author's transl)].
Koenig, A; Lauven, PM; Schüttler, J; Stoeckel, H; Wilms, M, 1980
)
0.26
" Plasma concentrations fitted best to an open three compartment pharmacokinetic model by a non-linear regression computer programme."( Pharmacokinetics of etomidate in surgical patients.
Breimer, DD; de Boer, AG; de Ruiter, G; Popescu, DT; Smeekens, JB, 1981
)
0.26
"The superposition principle of linear pharmacokinetics allows in a simple way simulation of blood levels and amounts of drug in other compartments for arbitrary dosage schemes provided the pharmacokinetic data are known."( [Comparison of various empirical dosage suggestions for etomidate infusions on the basis of pharmacokinetic data (author's transl)].
Lauven, P; Schüttler, J; Schwilden, H; Stoeckel, H, 1981
)
0.26
" In conclusion, an increased hypnotic effect of etomidate was observed during hypovolemia that is mainly attributed to pharmacokinetic changes."( Influence of hypovolemia on the pharmacokinetics and the electroencephalographic effect of etomidate in the rat.
Belpaire, FM; Boon, PA; Buylaert, WA; De Paepe, P; Van Hoey, G, 1999
)
0.3
" Pharmacokinetic modeling of the data showed that metomidate had shorter elimination half-life and higher plasma concentrations in turbot compared with halibut, both species displaying a rapid uptake, distribution and excretion."( Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus).
Hansen, MK; Horsberg, TE; Nymoen, U, 2003
)
0.32
" Pharmacokinetic variables for each group were estimated by using a three-compartment model."( The influence of hemorrhagic shock on etomidate: a pharmacokinetic and pharmacodynamic analysis.
Egan, TD; Johnson, KB; Kern, SE; Layman, J; McJames, SW; White, JL, 2003
)
0.32
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"Early, intermediate and late pharmacokinetic phases could be isolated in this manner."( Masked volume wise Principal Component Analysis of small adrenocortical tumours in dynamic [11C]-metomidate Positron Emission Tomography.
Hellman, P; Hennings, J; Långström, B; Monazzam, A; Razifar, P; Sundin, A, 2009
)
0.35
"This study established the pharmacokinetic and pharmacodynamic relationships of the bispectral index (BIS) and Observer's Assessment of Alertness/Sedation (OAA/S) scale with effect site drug concentrations during and after brief etomidate infusion."( Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers.
Han, TH; Kaneda, K; Woo, S; Yamashita, S, 2011
)
0.37
" Pharmacokinetic data to help guide dosing in neonates and infants are lacking."( Population pharmacokinetics of etomidate in neonates and infants with congenital heart disease.
Cohane, CA; Drover, DR; El-Komy, MH; Frymoyer, A; Hammer, GB; Su, F, 2015
)
0.42
" A population pharmacokinetic approach using nonlinear mixed-effects modeling was applied to characterize etomidate pharmacokinetics."( Population pharmacokinetics of etomidate in neonates and infants with congenital heart disease.
Cohane, CA; Drover, DR; El-Komy, MH; Frymoyer, A; Hammer, GB; Su, F, 2015
)
0.42
" Pharmacokinetic parameters were calculated."( A Phase 1, Single-center, Double-blind, Placebo-controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Clinical Effects, and Pharmacokinetics-Pharmacodynamics of Intravenous Cyclopropyl-methoxycarbonylmetomidate (ABP-700) after a Single
Absalom, AR; Campagna, JA; Chou, T; den Daas, I; Eleveld, DJ; Meier, S; Meyer, P; Struys, MMRF; Sweeney, SP; Valk, BI; van Amsterdam, K, 2017
)
0.46
" A three-compartment pharmacokinetic model described the data well."( A Phase 1, Single-center, Double-blind, Placebo-controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Clinical Effects, and Pharmacokinetics-Pharmacodynamics of Intravenous Cyclopropyl-methoxycarbonylmetomidate (ABP-700) after a Single
Absalom, AR; Campagna, JA; Chou, T; den Daas, I; Eleveld, DJ; Meier, S; Meyer, P; Struys, MMRF; Sweeney, SP; Valk, BI; van Amsterdam, K, 2017
)
0.46
" In order to facilitate the pharmacokinetic study, a liquid chromatography based tandem mass spectrometric (HPLC-MS/MS) method was developed and validated for quantification of ET-26-HCl and its major metabolite, ET-26-acid."( An HPLC tandem mass spectrometry for quantification of ET-26-HCl and its major metabolite in plasma and application to a pharmacokinetic study in rats.
Chen, X; Jiang, X; Li, G; Morkos, MB; Rios, S; Wang, L; Wang, Z; Ye, X; Zhang, W, 2018
)
0.48
" Distribution and excretion were assessed in rats and pharmacokinetic studies were performed in beagle dogs."( Preclinical Pharmacokinetics Study of a Novel Intravenous Anesthetic ET-26 Hydrochloride.
Deng, C; Gong, D; Kang, Y; Liu, J; Yang, J; Zhang, W; Zhang, YJ, 2019
)
0.51
" In dogs, pharmacokinetic features of ET-26 hydrochloride had a linear relationship with dosage."( Preclinical Pharmacokinetics Study of a Novel Intravenous Anesthetic ET-26 Hydrochloride.
Deng, C; Gong, D; Kang, Y; Liu, J; Yang, J; Zhang, W; Zhang, YJ, 2019
)
0.51
" Because of the decrease in popularity of etomidate, few modern extensive pharmacokinetic or pharmacodynamic studies exist."( Etomidate and its Analogs: A Review of Pharmacokinetics and Pharmacodynamics.
Struys, MMRF; Valk, BI, 2021
)
0.62
" For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1."( Obstructive Jaundice does not Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery.
Cai, MH; Gao, H; Meng, XY; Song, JC; Yang, H; Yu, WF; Zhang, MZ, 2022
)
0.72

Compound-Compound Interactions

Etomidate in combination with oxycodone for painless gastroscopic operation in the elderly is a safe and effective anesthetic strategy.

ExcerptReferenceRelevance
" Therefore the application of etomidate as a continuous infusion in combination with fentanyl and nitrous oxide 66% seems to be an effective technique of intravenous anaesthesia."( [The influence on the cardiovascular system of etomidate infusion anaesthesia combined with fentanyl/nitrous oxide (author's transl)].
Hoffmann, P; Schockenhoff, B, 1981
)
0.26
"Anaesthesia in guinea pigs with a new highly potent and short-acting analgesic, carfentanyl (R 33799), combined with the hypnotic, etomidat (R 26490), is reported."( A new highly potent and short-acting analgesic, carfentanyl (R 33799), in combination with the hypnotic agent, etomidat (R 26490), as a method of anaesthesia in guinea pigs.
Blümel, G; Erhardt, W; Fritsch, R; Neumann, G; Oberhuber, B, 1980
)
0.26
" Anesthesia was maintained with either propofol or etomidate combined with remifentanil."( Comparison of the effects of etomidate and propofol combined with remifentanil and guided by comparable BIS on transcranial electrical motor-evoked potentials during spinal surgery.
Cheng, H; Han, RQ; Liu, HY; Qiao, H; Wang, MR; Zeng, HY, 2012
)
0.38
" In addition, etomidate in combination with fentanyl had a shorter induction time and ensured haemodynamic stability."( Anaesthesia for cardioversion: a prospective randomised comparison of propofol and etomidate combined with fentanyl.
Askitopoulou, H; Kalogridaki, M; Kanoupakis, EM; Kasotaki, S; Mavrakis, HE; Panteli, A; Souvatzis, X; Vardas, P,
)
0.13
"The aim of this study was to investigate and evaluate the safety, recovery time, and side effects of general anesthesia with different doses of etomidate emulsion combined with remifentanil."( Clinical study of etomidate emulsion combined with remifentanil in general anesthesia.
Huang, M; Jiang, R; Weng, D; Yang, C; Zhan, R, 2013
)
0.39
"Continuous infusion of etomidate emulsion at 10 μg · kg(-1) · minute(-1) combined with remifentanil during anesthesia has the advantages of hemodynamic stability, quick wake-up, and few adverse reactions."( Clinical study of etomidate emulsion combined with remifentanil in general anesthesia.
Huang, M; Jiang, R; Weng, D; Yang, C; Zhan, R, 2013
)
0.39
" In the present study, we investigated the effects of TAES combined with low-dose sufentanil pretreatment on the incidence and severity of etomidate-induced myoclonus in patients undergoing elective hysteroscopy."( Effects of transcutaneous acupoint electrical stimulation combined with low-dose sufentanil pretreatment on the incidence and severity of etomidate-induced myoclonus: A randomized controlled trial.
Dai, Q; Geng, W; He, H; Jin, W; Lv, Y; Mo, Y; Pan, Y; Shou, C; Wang, J; Wang, L; Xie, J, 2018
)
0.48
"Our results suggest that TAES combined with low-dose opioids such as sufentanil can decrease the incidence and severity of etomidate-induced myoclonus."( Effects of transcutaneous acupoint electrical stimulation combined with low-dose sufentanil pretreatment on the incidence and severity of etomidate-induced myoclonus: A randomized controlled trial.
Dai, Q; Geng, W; He, H; Jin, W; Lv, Y; Mo, Y; Pan, Y; Shou, C; Wang, J; Wang, L; Xie, J, 2018
)
0.48
" This study examined the clinical effects of dexmedetomidine hydrochloride combined with etomidate fat emulsion in patients undergoing interventional treatment of stroke during anesthesia."( Clinical effects and safety evaluation of dexmedetomidine hydrochloride combined with etomidate fat emulsion in patients undergoing interventional treatment of stroke during anesthesia.
Luo, W; Xiao, ZY; Xiong, Y, 2018
)
0.48
" Group A patients were treated with dexmedetomidine hydrochloride, group B patients were treated with etomidate fat emulsion, and group C patients were treated with dexmedetomidine hydrochloride combined with etomidate fat emulsion."( Clinical effects and safety evaluation of dexmedetomidine hydrochloride combined with etomidate fat emulsion in patients undergoing interventional treatment of stroke during anesthesia.
Luo, W; Xiao, ZY; Xiong, Y, 2018
)
0.48
"Dexmedetomidine hydrochloride combined with etomidate fat emulsion in patients undergoing interventional treatment of stroke during anesthesia has potential value in clinical applications, through the maintenance of ideal hemodynamics and a reduction in complications."( Clinical effects and safety evaluation of dexmedetomidine hydrochloride combined with etomidate fat emulsion in patients undergoing interventional treatment of stroke during anesthesia.
Luo, W; Xiao, ZY; Xiong, Y, 2018
)
0.48
"To investigate the effects of etomidate, emulsified isoflurane, and their combination with dexmedetomidine on physiological parameters, electrocardiogram (ECG) results, and the quality of induction and recovery during isoflurane maintenance anaesthesia."( Dexmedetomidine combined with etomidate or emulsified isoflurane for induction reduced cardiopulmonary response in dogs.
Lin, T; Liu, C; Zhou, Z, 2018
)
0.48
" The objective was to observe the effect of etomidate combined with dexmedetomidine on adrenocortical function in elderly patients."( Effects of etomidate combined with dexmedetomidine on adrenocortical function in elderly patients: a double-blind randomized controlled trial.
Gao, L; Li, J; Wang, F; Wang, N; Yang, Z; Zeng, S, 2022
)
0.72
"In order to explore more ideal intravenous anesthesia drug in clinical practice, the analgesic effect of remazolam combined with etomidate in painless gastroenteroscopy and its effect on stress response is investigated."( Analysis of Stress Response and Analgesic Effect of Remazolam Combined with Etomidate in Painless Gastroenteroscopy.
Liu, G; Xiong, Y, 2022
)
0.72
" We conducted a prospective randomized controlled trial to compare etomidate alone with etomidate combined with oxycodone in elderly patients undergoing painless gastroscopy."( Safety and efficacy of etomidate in combination with oxycodone in painless gastroscopic procedures in the elderly: A prospective randomized controlled trial study.
Li, YP; Zhou, Y, 2023
)
0.91
"Etomidate in combination with oxycodone for painless gastroscopic operation in the elderly is a safe and effective anesthetic strategy."( Safety and efficacy of etomidate in combination with oxycodone in painless gastroscopic procedures in the elderly: A prospective randomized controlled trial study.
Li, YP; Zhou, Y, 2023
)
0.91
"To evaluate the adverse effects and particularly the anesthetic effect of low-dose etomidate combined with oxycodone and midazolam in endoscopic injection sclerotherapy."( Application of low-dose etomidate combined with oxycodone and midazolam in endoscopic injection sclerotherapy.
Cao, Y; Hao, S; Quan, Z; Yao, J; Zhou, C, 2023
)
0.91
"Low-dose etomidate combined with oxycodone and midazolam for endoscopic injection sclerotherapy could reduce the incidence of hypoxia without increasing the incidence of complications."( Application of low-dose etomidate combined with oxycodone and midazolam in endoscopic injection sclerotherapy.
Cao, Y; Hao, S; Quan, Z; Yao, J; Zhou, C, 2023
)
0.91
"This study examined how etomidate combined with propofol affected cognitive function, inflammation, and immunity in patients undergoing gastric cancer surgery."( Influences of Etomidate Combined with Propofol on Cognitive Function, Inflammation and Immunity in Patients Undergoing Gastric Cancer Surgery.
Tian, X, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Diazepam, which produces good tranquilization, is well absorbed when given orally though absorption is influenced by other drugs given at the same time."( New drugs--boon or bane? Premedication and intravenous induction agents.
Clarke, RS, 1983
)
0.27
" Our objective was to study the oral mucosal absorption kinetics and bioavailability of etomidate in a solid dose form in dogs."( Buccal absorption of etomidate from a solid formulation in dogs.
Coleman, D; Hague, B; Maland, L; Niu, S; Robertson, S; Stanley, TH; Streisand, JB; Zhang, J, 1998
)
0.3
" The oral bioavailability (F) was calculated to 100% in turbot."( Pharmacokinetic and pharmacodynamic properties of metomidate in turbot (Scophthalmus maximus) and halibut (Hippoglossus hippoglossus).
Hansen, MK; Horsberg, TE; Nymoen, U, 2003
)
0.32
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Etomidate produced progressive slowing of the EEG to an easily recognized pattern (stage 3) that determined the dosage endpoint. Propofol's effect on reducing the incidence and severity of myoclonic movements induced by etomidate increased. The dependence of Cl(1), V(1) on age does not support weight-based etomidates dosing in smaller children.

ExcerptRelevanceReference
"An investigation was undertaken to determine the dosage of etomidate required to maintain sleep in adults undergoing surgery under regional local anesthesia."( Total intravenous anesthesia with etomidate. III. Some observations in adults.
Kay, B; Rolly, G, 1977
)
0.26
" Examples of EEG dependence on the kind of anesthesia, the age of the patient, and individual sensitivity to the dosage of the anesthetic agent are given."( [Pre and postoperative EEG monitoring as illustrated in various routine anesthesia methods].
Gubernatis, G; Lips, U; Pichlmayr, J, 1978
)
0.26
" The etomidate dosage chosen more often gave an immediate satisfactory sleep."( A comparative study of etomidate and methohexital as induction agents for analgesic anesthesia.
Bastenier-Geens, J; Dubois-Primo, J; Genicot, C; Rucquoi, M, 1976
)
0.26
"On the basis stochastic control techniques, an algorithm for the design of dosing regimens is developed."( Open-loop stochastic control of pharmacokinetic systems: a new method for design of dosing regimens.
Lago, PJ, 1992
)
0.28
" In each patient the dosage of the drugs was adjusted to obtain the optimum responses during induction and maintenance."( [Propofol for induction and maintenance of anesthesia during heart surgery. Results of pharmacological studies in man].
Haverich, A; Kirchner, E; Lübbe, N; Schaps, D; Seitz, W, 1991
)
0.28
" The dose-response relationship also was determined in 15 normal subjects."( Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects.
Allolio, B; Benker, G; Reinwein, D; Schulte, HM; Sippell, WG, 1990
)
0.28
" In conclusion, a 30% higher etomidate bolus dosage is required in children than in adults to achieve similar plasma concentrations, due to a higher volume of the initial compartment."( [Comparison of the pharmacokinetics of etomidate in children and in adults].
Gaillard, JL; Le Mapihan, Y; Le Moing, JP; Levron, JC; Rosemblatt, JM; Sfez, M, 1990
)
0.28
" Spearman's rank correlation test shows a significant relationship between increasing etomidate dosage and both decreased SI and increased SVR."( [Hemodynamic effects of etomidate in the child: a study of the dose-effect relation].
Gaillard, JL; Le Mapihan, Y; Rosemblatt, JM; Sfez, M, 1989
)
0.28
"We studied the effect of low dosage (0."( Missing effect of etomidate on testosterone secretion in man.
Allolio, B; Stuttmann, R; Winkelmann, W, 1986
)
0.27
" Etomidate produced progressive slowing of the EEG to an easily recognized pattern (stage 3) that determined the dosage endpoint."( Increased sensitivity to etomidate in the elderly: initial distribution versus altered brain response.
Arden, JR; Holley, FO; Stanski, DR, 1986
)
0.27
"Alfentanil in combination with etomidate and N2O/O2 was given to 50 patients as single dosage (0."( [Alfentanil in routine clinical use. A study of 50 patients].
Löffler, B, 1985
)
0.27
" The dosage of etomidate and methohexitone was lowe than that reported in the literature."( [Etomidate versus methohexital for intravenous anesthesia with alfentanyl and nitrous oxide-oxygen. A double-blind study of circulatory behavior and postoperative course].
Papst-Baierl, D; Sold, M; Weis, KH, 1985
)
0.27
" The endexpiratory percentage CO2-concentration and the expiratory percentage O2-concentration were determined under anesthesia by means of adequate dosage of anesthetics in two groups (group I: 16 women aged between 16 and 54; group II: 10 women aged between 60 and 75)."( [Radenarcon/fentanyl short anesthesias in small gynecologic interventions].
Beutner, M; Fiedler, C; Siegismund, K, 1983
)
0.27
" The use of results obtained from the first group of six patients enabled a dosage regimen to be calculated that used a two stage infusion."( Plasma concentrations of etomidate during an intravenous infusion over 48 hours.
Hebron, BS, 1983
)
0.27
" In Group 2, 20 patients received the same dosage of etomidate to supplement spinal anaesthesia for lower abdominal surgery."( Etomidate infusion. Its use in anaesthesia for general surgery.
Scorgie, B, 1983
)
0.27
"The superposition principle of linear pharmacokinetics allows in a simple way simulation of blood levels and amounts of drug in other compartments for arbitrary dosage schemes provided the pharmacokinetic data are known."( [Comparison of various empirical dosage suggestions for etomidate infusions on the basis of pharmacokinetic data (author's transl)].
Lauven, P; Schüttler, J; Schwilden, H; Stoeckel, H, 1981
)
0.26
" Log-probit dose-response curves for these end-points and for lethal effect were determined."( The indices of potency for intravenous anaesthetics.
Kissin, I; McGee, T; Smith, LR, 1981
)
0.26
" Ketamine-fentanyl-propofol combination at a dosage of 30-0."( Comparison of anesthesia induced by ketamine-fentanyl combination and maintained by propofol or etomidate in New Zealand white rabbits.
Griffith, JW; Lang, CM; Luo, Y; Russell, GB, 1995
)
0.29
"This study was designed to evaluate the dose-response effects of different doses of clonidine on the stress response to laryngoscopy and endotracheal intubation."( Dose-response effects of intravenous clonidine on stress response during induction of anesthesia in coronary artery bypass graft patients.
Kulka, PJ; Tryba, M; Zenz, M, 1995
)
0.29
" Inadequate doses or dosing regimens should be avoided."( Pharmacology of intravenous sedatives and opioids in critically ill patients.
Levine, RL, 1994
)
0.29
" The dose-response effects of etomidate, propofol and their respective vehicles on neutrophil function were tested by FMLP- and zymosan-induced chemiluminescence of neutrophils and, in addition, in a cell-free chemiluminescence system."( Do etomidate and propofol influence oxygen radical production of neutrophils?
Birkhahn, A; Krone, M; Schneider, EM; Weiss, M, 1996
)
0.29
"The anesthetic induction agents were repeated at the same dosage when cardiopulmonary bypass was instituted."( Bolus administration of eltanolone, thiopental, or etomidate does not affect systemic vascular resistance during cardiopulmonary bypass.
Jänicke, U; Martin, K; Ott, E; Tassani, P, 1997
)
0.3
" This is the first study in humans to examine the oral transmucosal administration of a novel etomidate dosage form."( Oral transmucosal etomidate in volunteers.
Badger, MJ; Gay, MA; Jaarsma, RL; Maland, L; Nordbrock, E; Stanley, TH; Streisand, JB, 1998
)
0.3
" Further development of this novel dosage form is warranted."( Oral transmucosal etomidate in volunteers.
Badger, MJ; Gay, MA; Jaarsma, RL; Maland, L; Nordbrock, E; Stanley, TH; Streisand, JB, 1998
)
0.3
" This report suggests that, in extrapolating in vitro dose-response relationships to those from in vivo conditions, the effect of the concentration of extracellular protein can be estimated."( Interaction of extracellular albumin and intravenous anaesthetics, etomidate and propofol, on calcium signalling in rat airway smooth muscle cells.
Belouchi, NE; Marthan, R; Roux, E; Savineau, JP,
)
0.13
"Demographics, dosing information, recovery times, and adverse events were abstracted using a standardized data collection form."( Etomidate for procedural sedation in the emergency department.
Davis, V; Erstad, BL; Keim, SM; Sakles, JC, 2002
)
0.31
" In this study, pretreatment with a small dosage of etomidate or midazolam was compared with placebo for the prevention of myoclonic muscle movements."( Midazolam pretreatment reduces etomidate-induced myoclonic movements.
Fritz, HG; Hueter, L; Schwarzkopf, KR; Simon, M, 2003
)
0.32
"3 mg/kg), and to compare the accuracy of the dosing of midazolam for ED RSI with the accuracy of dosing of other agents."( Underdosing of midazolam in emergency endotracheal intubation.
Barton, ED; Chiang, V; Sagarin, MJ; Sakles, JC; Vissers, RJ; Walls, RM, 2003
)
0.32
" More than half (56%) of the children, and nearly all (92%) of the adults, received dosages lower than the minimum recommended dosage (0."( Underdosing of midazolam in emergency endotracheal intubation.
Barton, ED; Chiang, V; Sagarin, MJ; Sakles, JC; Vissers, RJ; Walls, RM, 2003
)
0.32
"Underdosing of midazolam during ED RSI is frequent, and appears to be related to incorrect dosage selection, rather than to a deliberate intention to reduce the dose used."( Underdosing of midazolam in emergency endotracheal intubation.
Barton, ED; Chiang, V; Sagarin, MJ; Sakles, JC; Vissers, RJ; Walls, RM, 2003
)
0.32
"A total of 61 patients were enrolled in the study (27 etomidate group, 34 pentobarbital group) at 2 different dosing regimens for etomidate."( Etomidate versus pentobarbital for sedation of children for head and neck CT imaging.
Hunter, J; Kienstra, AJ; Macias, CG; Morriss, MC; Sasan, F; Ward, MA, 2004
)
0.32
"At the dosing used in this study, pentobarbital is superior to etomidate when comparing success rates for sedation."( Etomidate versus pentobarbital for sedation of children for head and neck CT imaging.
Hunter, J; Kienstra, AJ; Macias, CG; Morriss, MC; Sasan, F; Ward, MA, 2004
)
0.32
" In endothelium-intact rings precontracted with phenylephrine 10(-6) M, dose-response curves for acetylcholine (10(-9) to 10(-5) M) and calcium ionophore (10(-9) to 10(-6) M) were generated in the presence and absence of etomidate (5 x10(-6) 10(-5) M)."( Effect of etomidate on endothelium-dependent relaxation induced by acetylcholine in rat aorta.
Cho, HC; Chung, YK; Kim, HJ; Lee, HK; Shin, IW; Sohn, JT, 2004
)
0.32
" Also gaboxadol dose-response curves followed the same sensitivity rank order, with EC50 values being 72 and 411 microM for alpha3beta1epsilon and alpha3beta1gamma2 subtypes, respectively."( Impact of epsilon and theta subunits on pharmacological properties of alpha3beta1 GABAA receptors expressed in Xenopus oocytes.
Korpi, ER; Möykkynen, T; Ranna, M; Sinkkonen, ST; Uusi-Oukari, M, 2006
)
0.33
" This dosage was administered only when enrolled patients had acute elevations of intracranial pressure (ICP) to over 20 mm Hg for over 5 minutes."( The effect of etomidate on intracranial pressure and systemic blood pressure in pediatric patients with severe traumatic brain injury.
Bramwell, KJ; Haizlip, J; Pribble, C; VanDerHeyden, TC; Witte, M, 2006
)
0.33
"The time and the dosage of etomidate necessary to loss consciousness were greater in group F ((70."( Peri-intubation hemodynamic changes during low dose fentanyl, remifentanil and sufentanil combined with etomidate for anesthetic induction.
Sun, L; Zhang, GH, 2009
)
0.35
" A 1 mL/kg dosage of a 300 mg/mL solution of iohexol was administered at a rate of 3 mL/s during GFR measurement."( Evaluation of the effects of thiopental, propofol, and etomidate on glomerular filtration rate measured by the use of dynamic computed tomography in dogs.
Chang, D; Chang, J; Choi, M; Jung, J; Kim, S; Lee, H; Lee, I; Lee, Y; Yoon, J, 2011
)
0.37
" The dependence of Cl(1) and V(1) on age does not support weight-based etomidate dosing in smaller children."( Population pharmacokinetics of intravenous bolus etomidate in children over 6 months of age.
Bai, J; Cai, MH; Huang, Y; Lin, L; Zhang, JW; Zhang, MZ, 2012
)
0.38
" Because of these properties, we hypothesized that dosing would be lower and electroencephalographic and hypnotic recoveries would be faster - and less context-sensitive - with DMMM or CPMM versus methoxycarbonyl etomidate or etomidate."( Electroencephalographic and hypnotic recoveries after brief and prolonged infusions of etomidate and optimized soft etomidate analogs.
Cotten, JF; Ge, R; Husain, SS; Pejo, E; Raines, DE, 2012
)
0.38
" The results also demonstrate the presence of interactions between allosteric activators and potentiators, raising a possibility of effects on dosage requirements or changes in side effects."( The benzodiazepine diazepam potentiates responses of α1β2γ2L γ-aminobutyric acid type A receptors activated by either γ-aminobutyric acid or allosteric agonists.
Akk, G; Eaton, MM; Li, P; Steinbach, JH, 2013
)
0.39
" Co-application of neurosteroids with etomidate can significantly reduce dosage requirements for the anaesthetic, and is a potentially beneficial combination to reduce undesired side effects."( The neurosteroid 5β-pregnan-3α-ol-20-one enhances actions of etomidate as a positive allosteric modulator of α1β2γ2L GABAA receptors.
Akk, G; Bracamontes, JR; Evers, AS; Li, P; Manion, BD; Mennerick, S; Steinbach, JH, 2014
)
0.4
" Pharmacokinetic data to help guide dosing in neonates and infants are lacking."( Population pharmacokinetics of etomidate in neonates and infants with congenital heart disease.
Cohane, CA; Drover, DR; El-Komy, MH; Frymoyer, A; Hammer, GB; Su, F, 2015
)
0.42
" The hypnotic potencies of etomidate analogs were defined using a loss of righting reflexes assay in Sprague Dawley rats (n = 9 to 21 measurements per dose-response curve)."( γ-Aminobutyric Acid Type A Receptor Modulation by Etomidate Analogs.
Dershwitz, P; Husain, SS; Pejo, E; Raines, DE; Santer, P; Wang, L, 2016
)
0.43
"There are limited data regarding appropriateness of sedative and paralytic dosing of obese patients undergoing rapid sequence intubation (RSI) in the emergency department."( Accuracy of rapid sequence intubation medication dosing in obese patients intubated in the ED.
Bhat, R; Dynin, M; Goyal, M; Mazer-Amirshahi, M; Sun, C; Tefera, E; Towle, D; Vaughns, J, 2016
)
0.43
" Dosing for succinylcholine and etomidate was calculated as milligrams per kilogram of total body weight (TBW) for each patient, defining appropriate dosing as succinylcholine 1-1."( Accuracy of rapid sequence intubation medication dosing in obese patients intubated in the ED.
Bhat, R; Dynin, M; Goyal, M; Mazer-Amirshahi, M; Sun, C; Tefera, E; Towle, D; Vaughns, J, 2016
)
0.43
" Most obese and nonobese patients were inappropriately dosed with RSI medications, suggesting that physicians are not dosing these medications based on weight."( Accuracy of rapid sequence intubation medication dosing in obese patients intubated in the ED.
Bhat, R; Dynin, M; Goyal, M; Mazer-Amirshahi, M; Sun, C; Tefera, E; Towle, D; Vaughns, J, 2016
)
0.43
" Etomidate, mean dosage (SD) = 0."( S -ketamine compared to etomidate during electroconvulsive therapy in major depression.
Ahrens, K; Dannlowski, U; Dietsche, P; Kircher, T; Kluge, I; Köhnlein, B; Konrad, C; Wohltmann, T; Zavorotnyy, M, 2017
)
0.46
" Secondary objectives were to characterize the pharmacokinetics of ABP-700 and its primary metabolite (cyclopropyl-methoxycarbonyl acid), to assess the clinical effects of ABP-700, and to investigate the dose-response and pharmacokinetic/pharmacodynamic relationships."( A Phase 1, Single-center, Double-blind, Placebo-controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Clinical Effects, and Pharmacokinetics-Pharmacodynamics of Intravenous Cyclopropyl-methoxycarbonylmetomidate (ABP-700) after a Single
Absalom, AR; Campagna, JA; Chou, T; den Daas, I; Eleveld, DJ; Meier, S; Meyer, P; Struys, MMRF; Sweeney, SP; Valk, BI; van Amsterdam, K, 2017
)
0.46
" Furthermore, as propofol dosage increased, its effect on reducing the incidence and severity of myoclonic movements induced by etomidate increased."( Propofol decreases etomidate-related myoclonus in gastroscopy.
Cai, Z; Dai, X; Deng, C; Liu, J; Liu, R; Meng, C; Zhang, J; Zhou, H, 2017
)
0.46
" NMBA dosing was reported descriptively."( Effect of patient weight on first pass success and neuromuscular blocking agent dosing for rapid sequence intubation in the emergency department.
Patanwala, AE; Sakles, JC, 2017
)
0.46
"We recently published a comparison of two hydrocortisone dosage regimens in patients with septic shock."( Is Inappropriate Response to Cosyntropin Stimulation Test an Indication of Corticosteroid Resistance in Septic Shock?
Barel, R; Bernardin, G; Dellamonica, J; Doyen, D; Goubaux, B; Hyvernat, H; Kaidomar, M; Panaïa-Ferrari, P; Pradier, C, 2018
)
0.48
" Flunixin meglumine at the 25-mg/kg dose provided analgesic relief at the latest time point during etomidate dosage and at all time points during benzocaine dosage, but further characterization is warranted regarding long-term or repeated analgesic administration."( Comparison of Etomidate, Benzocaine, and MS222 Anesthesia with and without Subsequent Flunixin Meglumine Analgesia in African Clawed Frogs (
Carroll, GL; Elliott, JJ; Jeffery, ND; Smith, BD; Taylor, MC; Vail, KJ; Vemulapalli, TH, 2018
)
0.48
" Involuntary muscle movements (IMM) were reported, which were more extensive with higher dosing regimens."( Safety and clinical effect of i.v. infusion of cyclopropyl-methoxycarbonyl etomidate (ABP-700), a soft analogue of etomidate, in healthy subjects.
Absalom, AR; Campagna, JA; den Daas, I; Meier, S; Meyer, P; Struys, MMRF; Sweeney, SP; Valk, BI; van Amsterdam, K, 2018
)
0.48
" Mean peak plasma concentrations were (from lowest to highest dosed groups) 35 μM, 45 μM, and 102 μM (ABP-700) and 282 μM, 478 μM, and 1,110 μM (CPM-acid)."( Toxicologic and Inhibitory Receptor Actions of the Etomidate Analog ABP-700 and Its Metabolite CPM-Acid.
Lehoux, D; Marota, JJA; McGrath, M; Raines, DE; Valk, BI; Zerler, B, 2019
)
0.51
" Dosing recommendations however are often based on strategies used in patients with normal body habitus."( Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium.
Barletta, JF; Erstad, BL, 2020
)
0.56
" However, its use and safe recommended dosage in infants with CS is unreported."( Using Etomidate in a Two-month-old Infant with Cushing Syndrome due to Adrenocortical Carcinoma
Choi, Y; Jung, JW; Kim, HS; Kwon, A; Suh, J, 2022
)
0.72
" There was a significant reduction in the etomidate induction dosage in both groups."( Comparison of the influence of low dose etomidate and propofol as priming dose on the incidence of etomidate induced myoclonus: a randomised, double-blind clinical trial.
Chikkala, R; Kulkarni, DK; Moningi, S; Nikhar, SA; Ramachandran, G; Reddy, GP,
)
0.13
" Further studies are needed to provide additional data for these and other species and families, for different water chemistry conditions, and for various biological factors to fine-tune dosing regimens."( Preliminary Investigations into Use of Metomidate for Euthanasia of Ornamental Fishes.
Yanong, RPE, 2021
)
0.62
" This study was aimed to investigate the physical and chemical stability of the mixture of etomidate and propofol in the dosage form of emulsion."( Physical and Chemical Compatibility of Etomidate and Propofol Injectable Emulsions.
Lei, L; Wang, C; Wang, DX; Wang, S; Wu, C; Zhang, Q, 2021
)
0.62
" Etomidate dosage was not associated with mortality in our study."( Independent risk factors of mortality in patients with sepsis receiving single-dose etomidate as an induction agent during rapid sequence intubation in a large tertiary emergency department in Thailand.
Chakorn, T; Limsuwat, C; Pansiritanachot, W; Ruangsomboon, O, 2022
)
0.72
" Inclusion criteria were the use of etomidate and/or methohexital and documentation of dosage, electroconvulsive therapy dosage and seizure duration."( The influence of anaesthetic choice on seizure duration of electroconvulsive therapy; etomidate versus methohexital.
Ahmadi, M; Chomrikh, L; Koopman, SJHA; Kuijper, TM; van der Vlugt, JJB, 2022
)
0.72
" Additional prospective studies are needed to determine optimal induction agent selection and dosing in patients presenting with shock or sepsis."( Pharmacotherapy optimization for rapid sequence intubation in the emergency department.
Brown, CS; Engstrom, K; Lyons, N; Mattson, AE; Rech, MA, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
intravenous anaestheticnull
sedativeA central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
ethyl esterAny carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (48)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency11.37430.000811.382244.6684AID686978
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency19.50600.001022.650876.6163AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.73770.01237.983543.2770AID1645841
pregnane X nuclear receptorHomo sapiens (human)Potency17.75790.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency3.62250.000229.305416,493.5996AID743069
GVesicular stomatitis virusPotency10.96400.01238.964839.8107AID1645842
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency56.23410.035520.977089.1251AID504332
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency3.16230.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency1.00000.004611.374133.4983AID624297
Interferon betaHomo sapiens (human)Potency10.96400.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency10.96400.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency10.96400.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency10.96400.01238.964839.8107AID1645842
EWS/FLI fusion proteinHomo sapiens (human)Potency37.22120.001310.157742.8575AID1259252
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.00000.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)61.61000.11007.190310.0000AID1449628
Acetylcholine receptor subunit alphaTetronarce californica (Pacific electric ray)IC50 (µMol)41.00000.00010.06770.3000AID147715
Acetylcholine receptor subunit betaTetronarce californica (Pacific electric ray)IC50 (µMol)41.00000.00010.06770.3000AID147715
Acetylcholine receptor subunit gammaTetronarce californica (Pacific electric ray)IC50 (µMol)41.00000.00010.06770.3000AID147715
Acetylcholine receptor subunit deltaTetronarce californica (Pacific electric ray)IC50 (µMol)41.00000.00010.06770.3000AID147715
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)IC50 (µMol)577.00000.00011.14948.0000AID72785
Cytochrome P450 11B1, mitochondrialHomo sapiens (human)IC50 (µMol)0.00050.00050.29022.7800AID1177643; AID459283; AID553065; AID652428
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)IC50 (µMol)577.00000.00011.29158.0000AID72785
Cytochrome P450 11B2, mitochondrialHomo sapiens (human)IC50 (µMol)0.00090.00010.27383.5000AID1177642; AID459282; AID553066; AID652429
Gamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)IC50 (µMol)577.00000.00010.93746.0000AID72785
TransporterRattus norvegicus (Norway rat)IC50 (µMol)41.00000.00081.95628.8000AID147715
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)EC50 (µMol)19.67500.00112.000910.0000AID360470; AID72308; AID72782; AID72783
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)EC50 (µMol)17.80000.00141.957810.0000AID240319; AID72308; AID72782; AID72783
Gamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)EC50 (µMol)3.50000.01201.17515.2000AID240319
Gamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)EC50 (µMol)17.80000.00141.776810.0000AID240319; AID72308; AID72782; AID72783
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (98)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
C21-steroid hormone biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
glucocorticoid biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
immune responseCytochrome P450 11B1, mitochondrialHomo sapiens (human)
regulation of blood pressureCytochrome P450 11B1, mitochondrialHomo sapiens (human)
sterol metabolic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
aldosterone biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cellular response to hormone stimulusCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cortisol biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cellular response to potassium ionCytochrome P450 11B1, mitochondrialHomo sapiens (human)
glucose homeostasisCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cholesterol metabolic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cortisol metabolic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cellular response to peptide hormone stimulusCytochrome P450 11B1, mitochondrialHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
post-embryonic developmentGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
adult behaviorGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cortisol biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
regulation of blood volume by renal aldosteroneCytochrome P450 11B2, mitochondrialHomo sapiens (human)
renal water homeostasisCytochrome P450 11B2, mitochondrialHomo sapiens (human)
C21-steroid hormone biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
mineralocorticoid biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
sterol metabolic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
aldosterone biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cellular response to hormone stimulusCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cortisol biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cellular response to potassium ionCytochrome P450 11B2, mitochondrialHomo sapiens (human)
potassium ion homeostasisCytochrome P450 11B2, mitochondrialHomo sapiens (human)
sodium ion homeostasisCytochrome P450 11B2, mitochondrialHomo sapiens (human)
glucocorticoid biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cortisol metabolic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cellular response to peptide hormone stimulusCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cholesterol metabolic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (37)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
steroid 11-beta-monooxygenase activityCytochrome P450 11B1, mitochondrialHomo sapiens (human)
iron ion bindingCytochrome P450 11B1, mitochondrialHomo sapiens (human)
heme bindingCytochrome P450 11B1, mitochondrialHomo sapiens (human)
corticosterone 18-monooxygenase activityCytochrome P450 11B1, mitochondrialHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
steroid 11-beta-monooxygenase activityCytochrome P450 11B2, mitochondrialHomo sapiens (human)
iron ion bindingCytochrome P450 11B2, mitochondrialHomo sapiens (human)
steroid hydroxylase activityCytochrome P450 11B2, mitochondrialHomo sapiens (human)
heme bindingCytochrome P450 11B2, mitochondrialHomo sapiens (human)
corticosterone 18-monooxygenase activityCytochrome P450 11B2, mitochondrialHomo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (45)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
mitochondrionCytochrome P450 11B1, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B1, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B1, mitochondrialHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
mitochondrionCytochrome P450 11B2, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B2, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B2, mitochondrialHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
extracellular exosomeGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (208)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID360474Protein binding in iv dosed human plasma2007The Journal of biological chemistry, Apr-20, Volume: 282, Issue:16
Identification of anesthetic binding sites on human serum albumin using a novel etomidate photolabel.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID72908Hill coefficient for enhancement of currents elicited by GABA at EC5 (6-12 uM)2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels.
AID527669Agonist activity at human GABA-A alpha-1-beta-2-gamma-2 receptor expressed in Xenopus laevis assessed as increase in channel current at 30 uM by electrophysiology relative to control2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
p-Trifluoromethyldiazirinyl-etomidate: a potent photoreactive general anesthetic derivative of etomidate that is selective for ligand-gated cationic ion channels.
AID240319Effective concentration against GABA-evoked chloride currents mediated by human Gamma-aminobutyric acid GABA-A receptor alpha2-beta2-gamma2L expressed in Xenopus oocytes2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis, structure-activity relationships at the GABA(A) receptor in rat brain, and differential electrophysiological profile at the recombinant human GABA(A) receptor of a series of substituted 1,2-diphenylimidazoles.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID72783Enhancement of currents elicited by GABA at EC5 (6-12 uM)2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels.
AID72782Ability to enhance currents from alpha-1-beta-2-gamma-2L-subunit of GABA receptor elicited by low concentrations of GABA2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels.
AID219913Anesthetic potency, Concentration for loss of righting reflexes (LORR) in Xenopus tadpoles2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels.
AID459284Selectivity ratio of IC50 for human CYP11B2 to IC50 human CYP11B12010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
AID109886Duration of analgesic action in mice was determined; B = brief, < 5 min1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.
AID360468Anesthetic potency in Rana temporaria tadpoles assessed as loss of righting reflex for 60 mins2007The Journal of biological chemistry, Apr-20, Volume: 282, Issue:16
Identification of anesthetic binding sites on human serum albumin using a novel etomidate photolabel.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID72784Maximum levels of enhancement of currents from alpha-1-beta-2-gamma-2L-subunit of GABA receptor elicited by low concentrations of GABA2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID459282Inhibition of human CYP11B2 expressed in chinese hamster V79 cells2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
AID427876Displacement of [3H]ethynylpropylbicycloorthobenzoate from GABA receptor from rat cortical membrane by scintillation counting in absence of GABA2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Structure-activity relationship of etomidate derivatives at the GABA(A) receptor: Comparison with binding to 11beta-hydroxylase.
AID114269Hypnotic activity was measured as dose which causes loss of righting reflex for a minimum period of 30s in 50% of mice; Range is 1-1.51980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.
AID116732Acute toxicity measured as median lethal dose in mice; Range is 40-451980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID360473Activation of human GABAA alpha-1-beta-2-gamma-2s receptor expressed in HEK293 cells2007The Journal of biological chemistry, Apr-20, Volume: 282, Issue:16
Identification of anesthetic binding sites on human serum albumin using a novel etomidate photolabel.
AID269962Reduction of [3H]flunitrazepam binding to cerebral cortex GABA-A receptor at 100 uM relative to control2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Synthesis of trifluoromethylaryl diazirine and benzophenone derivatives of etomidate that are potent general anesthetics and effective photolabels for probing sites on ligand-gated ion channels.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID553069Inhibition of human placental microsomes CYP19 at 500 nM using androstenedione substrate2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID527671Allosteric modulation of human GABAA alpha-1-beta-2-gamma-2 receptor expressed in Xenopus laevis assessed as enhancement of [3H]flunitrazepam binding up to 10 uM2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
p-Trifluoromethyldiazirinyl-etomidate: a potent photoreactive general anesthetic derivative of etomidate that is selective for ligand-gated cationic ion channels.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID72785Inhibition of currents elicited by GABA at EC5 (6-12 uM)2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1691856Positive allosteric modulation of GABAA alpha1beta3gamma2L S280W mutant (unknown origin) expressed in Xenopus laevis oocytes assessed as increase in GABA-induced current at 5 uM by two microelectrode voltage-clamp electrophysiology
AID1691855Positive allosteric modulation of GABAA alpha1beta3gamma2L S270I mutant (unknown origin) expressed in Xenopus laevis oocytes assessed as increase in GABA-induced current at 5 uM by two microelectrode voltage-clamp electrophysiology
AID360475Binding affinity to human serum albumin2007The Journal of biological chemistry, Apr-20, Volume: 282, Issue:16
Identification of anesthetic binding sites on human serum albumin using a novel etomidate photolabel.
AID327555Displacement of [131I]IMTO from CYP450c 11 in Wistar rat adrenal membrane2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
New selective inhibitors of steroid 11beta-hydroxylation in the adrenal cortex. Synthesis and structure-activity relationship of potent etomidate analogues.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID72311Maximum activation of Gamma-aminobutyric acid A receptor in the absence of GABA compared to GABA response2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID269951Anesthetic activity in Xenopus tadpole measured as loss of righting reflex2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Synthesis of trifluoromethylaryl diazirine and benzophenone derivatives of etomidate that are potent general anesthetics and effective photolabels for probing sites on ligand-gated ion channels.
AID652429Inhibition of human CYP11B2 expressed in hamster V79 MZ cells using [3H] 11 deoxycorticosterone as substrate by HPLC radioflow detector2011ACS medicinal chemistry letters, Aug-11, Volume: 2, Issue:8
Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID527665Agonist activity at human GABA-A alpha-1-beta-2-gamma-2 receptor expressed in Xenopus laevis assessed as increase in channel current at 5 uM by electrophysiology relative to control2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
p-Trifluoromethyldiazirinyl-etomidate: a potent photoreactive general anesthetic derivative of etomidate that is selective for ligand-gated cationic ion channels.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID147713Inhibition of recombinant embryonic mouse muscle Nicotinic Acetylcholine Receptor (3 oocytes)2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID553068Inhibition of human recombinant CYP17 expressed in Escherichia coli at 2 uM using progesterone substrate2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
AID1177643Inhibition of human CYP11B1 expressed in V79 MZ cells pretreated with compound for 1 hr followed by addition of 500 nM 11-deoxycorticosterone for 3 hrs by HPLC analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.
AID147715Inhibition of currents when compound wascoapplied with acetylcholine to recombinant Torpedo nAcChoR (from 6 oocytes)2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels.
AID360466Octanol-water partition coefficient, log KOW of the compound2007The Journal of biological chemistry, Apr-20, Volume: 282, Issue:16
Identification of anesthetic binding sites on human serum albumin using a novel etomidate photolabel.
AID72907Maximum response for enhancement of currents elicited by GABA at EC5 (6-12 uM)2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels.
AID327556Inhibition on cortisol secretion in human NCI-H295 cells after 48 hrs2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
New selective inhibitors of steroid 11beta-hydroxylation in the adrenal cortex. Synthesis and structure-activity relationship of potent etomidate analogues.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID269954Inhibition of 5HT3 receptor at 2.3 uM2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Synthesis of trifluoromethylaryl diazirine and benzophenone derivatives of etomidate that are potent general anesthetics and effective photolabels for probing sites on ligand-gated ion channels.
AID1691859Positive allosteric modulation of GABAA alpha1beta3gamma2L I242W mutant (unknown origin) expressed in Xenopus laevis oocytes assessed as increase in GABA-induced current at 5 uM by two microelectrode voltage-clamp electrophysiology
AID427875Displacement of [3H]ethynylpropylbicycloorthobenzoate from GABAA receptor from rat cortical membrane by scintillation counting in presence of 1 uM GABA2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Structure-activity relationship of etomidate derivatives at the GABA(A) receptor: Comparison with binding to 11beta-hydroxylase.
AID640615Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID553067Selectivity index, ratio of IC50 for human CYP11B2 to IC50 for human CYP11B12011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID246227Effective concentration required for reversible loss of righting reflex in Xenopus laevis tadpoles2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis, structure-activity relationships at the GABA(A) receptor in rat brain, and differential electrophysiological profile at the recombinant human GABA(A) receptor of a series of substituted 1,2-diphenylimidazoles.
AID427877Ratio of IC50 for rat cortical membrane GABA receptor in absence of GABA to IC50 for rat cortical membrane GABA receptor in presence of GABA2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Structure-activity relationship of etomidate derivatives at the GABA(A) receptor: Comparison with binding to 11beta-hydroxylase.
AID211464Concentration that reduced photoincorporation of [3H]azietomidate into the alpha and beta subunits of the nAcChoR in membranes of Torpedo electric organ2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels.
AID119873Speed of induction of analgesia in mice was determined; I = immediate, <10 s1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.
AID311935Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID269958Enhancement of [3H]flunitrazepam binding to cerebral cortex GABA-A receptor at >=1 uM2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Synthesis of trifluoromethylaryl diazirine and benzophenone derivatives of etomidate that are potent general anesthetics and effective photolabels for probing sites on ligand-gated ion channels.
AID72308Direct activation of Gamma-aminobutyric acid A receptor in the absence of GABA2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels.
AID527663Octanol-water partition coefficient, log P of the compound2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
p-Trifluoromethyldiazirinyl-etomidate: a potent photoreactive general anesthetic derivative of etomidate that is selective for ligand-gated cationic ion channels.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1691851Positive allosteric modulation of GABAA alpha1beta3gamma2L N265M mutant (unknown origin) expressed in Xenopus laevis oocytes assessed as increase in GABA-induced current at 5 uM by two microelectrode voltage-clamp electrophysiology
AID553065Inhibition of human CYP11B1 expressed in hamster V79MZ cells using 11-deoxycorticosterone substrate2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID527672Allosteric modulation of human GABAA alpha-1-beta-2-gamma-2 receptor expressed in Xenopus laevis assessed as enhancement of [3H]mucimol binding up to 10 uM2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
p-Trifluoromethyldiazirinyl-etomidate: a potent photoreactive general anesthetic derivative of etomidate that is selective for ligand-gated cationic ion channels.
AID244328Maximal efficacy for GABA-evoked chloride currents mediated by human Gamma-aminobutyric acid GABA-A receptor alpha2-beta2-gamma2L expressed in Xenopus oocytes2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis, structure-activity relationships at the GABA(A) receptor in rat brain, and differential electrophysiological profile at the recombinant human GABA(A) receptor of a series of substituted 1,2-diphenylimidazoles.
AID168704Anesthetic potency, Concentration for loss of righting reflexes (LORR) in Rana temporaria2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels.
AID652428Inhibition of human CYP11B1 expressed in hamster V79 MZ cells using [3H] 11 deoxycorticosterone as substrate by HPLC radioflow detector2011ACS medicinal chemistry letters, Aug-11, Volume: 2, Issue:8
Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID527676Displacement of [3H]GR65630 from 5HT3A receptor expressed in Xenopus oocyte2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
p-Trifluoromethyldiazirinyl-etomidate: a potent photoreactive general anesthetic derivative of etomidate that is selective for ligand-gated cationic ion channels.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID553066Inhibition of human CYP11B2 expressed in hamster V79MZ cells using 11-deoxycorticosterone substrate2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
AID652431Selectivity ratio of IC50 for human CYP11B2 to IC50 for human CYP11B12011ACS medicinal chemistry letters, Aug-11, Volume: 2, Issue:8
Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID527675Inhibition of 5HT3A receptor expressed in Xenopus oocyte at 300 uM2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
p-Trifluoromethyldiazirinyl-etomidate: a potent photoreactive general anesthetic derivative of etomidate that is selective for ligand-gated cationic ion channels.
AID459283Inhibition of human CYP11B1 expressed in chinese hamster V79 cells2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2).
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1691857Positive allosteric modulation of GABAA alpha1beta3gamma2L M227W mutant (unknown origin) expressed in Xenopus laevis oocytes assessed as increase in GABA-induced current at 5 uM by two microelectrode voltage-clamp electrophysiology
AID1177642Inhibition of human aldosterone synthase expressed in V79 MZ cells pretreated with compound for 1 hr followed by addition of 500 nM 11-deoxycorticosterone for 1hr by HPLC analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.
AID360470Activity at human GABAA alpha-1-beta-2-gamma-2s receptor expressed in HEK293 cells assessed as effect on GABA-induced current at 3 uM by whole cell patch-clamp technique2007The Journal of biological chemistry, Apr-20, Volume: 282, Issue:16
Identification of anesthetic binding sites on human serum albumin using a novel etomidate photolabel.
AID360472Activity at human GABAA alpha-1-beta-2-gamma-2s receptor N265M mutant expressed in HEK293 cells assessed as potentiation of GABA-induced current by whole cell patch-clamp technique2007The Journal of biological chemistry, Apr-20, Volume: 282, Issue:16
Identification of anesthetic binding sites on human serum albumin using a novel etomidate photolabel.
AID360471Activity at human GABAA alpha-1-beta-2-gamma-2s receptor expressed in HEK293 cells assessed as potentiation of GABA-induced current by whole cell patch-clamp technique2007The Journal of biological chemistry, Apr-20, Volume: 282, Issue:16
Identification of anesthetic binding sites on human serum albumin using a novel etomidate photolabel.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,963)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990614 (31.28)18.7374
1990's303 (15.44)18.2507
2000's408 (20.78)29.6817
2010's484 (24.66)24.3611
2020's154 (7.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 83.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index83.66 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index5.18 (4.65)
Search Engine Demand Index140.74 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (83.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials401 (19.36%)5.53%
Reviews0 (0.00%)6.00%
Reviews170 (8.21%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies138 (6.66%)4.05%
Observational0 (0.00%)0.25%
Observational13 (0.63%)0.25%
Other19 (100.00%)84.16%
Other1,349 (65.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (72)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Etomidate/Propofol Mixture or Propofol Monotherapy With Different Proportions on Circulation and Prognosis in Patients Undergoing General Anesthesia [NCT03855267]200 participants (Anticipated)Interventional2019-01-01Recruiting
Impact of Etomidate vs. Propofol on Development of Sepsis and Infectious Complications Post Cardiac Surgery [NCT04281706]1,495 participants (Actual)Observational2019-10-15Completed
Intra-articular Lidocaine vs Procedural Sedation for Anterior Shoulder Dislocations [NCT03625076]Phase 470 participants (Anticipated)Interventional2018-06-01Recruiting
Induction Agent and Incidence of Hypotension in Heart Failure Patients Undergoing LVAD-Implantation [NCT04934410]50 participants (Anticipated)Observational2021-11-01Not yet recruiting
[NCT02147678]Phase 4120 participants (Anticipated)Interventional2014-12-31Not yet recruiting
[NCT02174120]Phase 4120 participants (Anticipated)Interventional2014-10-31Not yet recruiting
The Safety of Etomidate - Propofol Mixture vs Propofol in Total Intravenous Anesthesia During Abdominal Surgery : a Randomized, Double-blind, Controlled, Multicenter Study [NCT05810363]468 participants (Anticipated)Interventional2023-06-16Recruiting
Effects of Different Doses of Dexmedetomidine on Postoperative Cognitive Dysfunction in Elderly Hypertensive Patients-A Single Center,Randomized, Double-blinded,Controlled Study [NCT02224443]Phase 490 participants (Anticipated)Interventional2014-09-30Not yet recruiting
Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial [NCT02643381]Phase 4801 participants (Actual)Interventional2016-06-06Completed
An Open Label, Single-Center, Single Dose Combination of HSK3486 and Etomidate Intravenous Bolus Injection to Determine the Safety, Pharmacodynamics and Pharmacokinetics for Induction of Anesthesia in Healthy Male Subjects [NCT04054063]Phase 125 participants (Actual)Interventional2016-11-30Completed
[NCT02186990]Phase 490 participants (Actual)Interventional2014-05-31Completed
[NCT02208596]Phase 4150 participants (Anticipated)Interventional2014-09-30Not yet recruiting
Comparison Between Inhalation and Intravenous Induction of Anaesthesia During Interventional Mitral Valve Repair [NCT04865614]57 participants (Actual)Observational2019-04-01Completed
Helping Stroke Patients With ThermoSuit Cooling [NCT02453373]14 participants (Actual)Interventional2017-01-25Terminated(stopped due to The study has achieved its objectives of showing feasibility, safety, and trend for improved mRS. FDA and LRS agreed that this study should be terminated, and that a new, PIVOTAL trial should be started.)
Safety and Efficacy of Maintenance of Etomidate Combined With Sevoflurane in General Anesthesia: a Multi-center Randomized Controlled Study [NCT05223907]Phase 41,080 participants (Anticipated)Interventional2021-05-01Recruiting
[NCT02182648]Phase 4120 participants (Anticipated)Interventional2014-10-31Not yet recruiting
A Randomized Controlled Trial to Evaluate the Hemodynamic Effects of Ketamine Versus Etomidate During Rapid Sequence Intubation [NCT03545503]Phase 4428 participants (Actual)Interventional2018-01-01Completed
Standardised Drug Provocation Testing in Perioperative Hypersensitivity [NCT06065137]Phase 450 participants (Anticipated)Interventional2023-10-31Not yet recruiting
Comparison of Induction Characteristics of Two Anaesthetic Agents-Etomidate Lipuro and Propofol [NCT02807610]Phase 4100 participants (Actual)Interventional2011-03-31Completed
General Anesthesia Versus Sedation During Intra-arterial Treatment for Stroke [NCT02822144]Phase 3351 participants (Actual)Interventional2016-09-29Completed
The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy: A Randomized Clinical Trial And Its Standard Technology Promotion Research [NCT02066077]280 participants (Actual)Interventional2013-01-01Completed
Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients -a Single-center, Randomized ,Double-blinded and Controlled Trial [NCT02134093]Phase 4120 participants (Anticipated)Interventional2014-07-31Not yet recruiting
Effect of Paravertebral Muscle Fat Infiltration on Rocuronium Use in Lumbar Surgery [NCT05619848]Early Phase 187 participants (Actual)Interventional2022-10-25Completed
Effect of Pre-injection of Lidocaine on Myoclonus Induced by Induction With Etomidate in Elderly Patients During General Anesthesia [NCT02141737]Phase 4272 participants (Anticipated)Interventional2014-05-31Recruiting
The Effect of Etomidate on Outcomes of Trauma Patients [NCT00938990]0 participants (Actual)InterventionalWithdrawn
Target Controlled Infusion of Etomidate or Propofol for Anesthesia of Thoracoscopic Mitral Valve Replacement Surgery,A Randomized Controlled Double-Blinded Study [NCT02644980]Phase 4110 participants (Anticipated)Interventional2015-12-31Not yet recruiting
Effect of Ketamine and Etomidate During Rapid Sequence Intubation on Long- Term Outcomes (Long-Term Outcomes of the RSI Trial) [NCT06179485]1,756 participants (Anticipated)Observational2022-04-06Recruiting
Effect of Remimazolam Induction on the Recovery Quality After Day Surgery in Elderly Patients: a Comparison Study With Etomidate [NCT05748665]112 participants (Anticipated)Interventional2023-08-14Recruiting
A Randomized Trial of Etomidate Versus Midazolam for Intubation of Patients With Sepsis. [NCT00441792]122 participants (Actual)Interventional2007-10-31Completed
Structural Brain Plasticity in Elderly Depressed Patients Following Electroconvulsive Therapy [NCT02667353]110 participants (Actual)Interventional2011-06-30Completed
Evaluating Duration and Depth of Anesthesia by Bispectral Index Induced by an Induction Dose of Etomidate. [NCT05862753]18 participants (Actual)Interventional2022-01-11Completed
The Randomized Trial of Sedative Choice for Intubation [NCT05277896]Phase 42,364 participants (Anticipated)Interventional2022-04-06Recruiting
Comparison of Effects on Hemodynamics Between Ketamine and Etomidate During Rapid Sequence Intubation in Trauma Patients With High Shock Index [NCT04120870]10 participants (Actual)Interventional2019-10-01Terminated(stopped due to Due to difficulties in obtaining consent because of emergency situation)
Prospective Study of Induction Medications Used in the Rapid Sequence Intubation of Trauma Patients and a Comparison of Effects on Outcomes [NCT04291521]7,000 participants (Anticipated)Observational2024-01-01Not yet recruiting
[NCT01386229]Phase 440 participants (Anticipated)Interventional2011-03-31Recruiting
A Comparative Study of the Efficacy and Safety of Etomidate Compared to Propofol in Gastric Endoscopic Submucosal Dissection: a Prospective, Single-center, Randomized, Double-blind, Non-inferiority Study [NCT05407870]138 participants (Anticipated)Interventional2022-06-09Recruiting
Combined Use of Etomidate and Propofol in Painless Gastroscopy, a Multiple Center, Double Blinded, Randomized,Controled Study. [NCT01913054]Phase 42,450 participants (Anticipated)Interventional2013-08-31Recruiting
[NCT02202239]Phase 460 participants (Anticipated)Interventional2014-09-30Not yet recruiting
Can Intravenous Lidocaine Decrease the Minimal Inducing Dose of Etomidate?: A Randomized Placebo-controlled Dose-response Study. [NCT01916642]Phase 1100 participants (Actual)Interventional2013-04-30Completed
The Influence of Induction Agents of General Anesthesia (Etomidate and Thiopental) on Serum Cortisol Concentration in Morbidly Obese Patients. A Randomized Controlled Trial. [NCT01930019]82 participants (Actual)Interventional2009-06-30Completed
Combined 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and 123I-Iodometomidate (123I-IMTO) Imaging for Adrenal Neoplasia [NCT02010957]Phase 3220 participants (Anticipated)Interventional2015-08-31Recruiting
Phase 1 Study of Circadian Rhythm of Salivary Cortisol in Health Children ;Phase 2 Study of Circadian Rhythm of Salivary Cortisol of Children Undergoing Surgery Using Etomidate or Not Using Etomidate. [NCT02013986]Phase 430 participants (Anticipated)Interventional2013-09-30Recruiting
Consumption of Rocuronium Under Etomidate-based Versus Propofol-based Maintenance of General Anesthesia Under Different Concentration of Sevoflurane- BIS Guided Clinical Trial in a Closed Loop Infusion System [NCT02711917]175 participants (Actual)Interventional2015-07-31Completed
The Changes in Cortisol Levels and Stress Responses During Cardiac Surgery. The Comparison Between Two Induction Agents: Etomidate and Thiopentone. [NCT01495949]Phase 492 participants (Actual)Interventional2011-12-31Completed
Etomidate Versus Propofol As An Anesthesia Induction Agent For Patients Undergoing CABG Surgery, Assessing Hemodynamic Stability. A Single Blinded, Randomized Controlled Trial. [NCT06068764]Phase 4300 participants (Anticipated)Interventional2023-12-05Recruiting
GUARDIAN (NCT04884802) Sub-study Comparing Etomidate and Propofol [NCT04934683]Phase 36,254 participants (Anticipated)Interventional2021-07-27Recruiting
Ketamine Versus Etomidate for Procedural Sedation for Pediatric Orthopedic Reductions [NCT00596050]Phase 450 participants (Actual)Interventional2006-08-31Completed
Post Operative Hemodynamic Function After Anesthetic Induction With Etomidate for Cardiac Surgery With ECC. A Prospective, Monocentric, Randomised Double Blind Study [NCT00451776]Phase 4100 participants (Actual)Interventional2007-06-30Completed
Ketamine Versus Etomidate During Rapid Sequence Intubation: Consequences on Hospital Morbidity [NCT00440102]Phase 4655 participants (Actual)Interventional2007-04-30Completed
Does Administration of Etomidate and Propofol if the Anesthetic Induction of the Elderly Hypertensive Patient Provide Superior Blood Pressure Stability in Response to Direct Laryngosacopy, When Compared to Propofol or Etomidate Alone? [NCT01248234]Phase 30 participants (Actual)Interventional2012-07-31Withdrawn(stopped due to Did not begin)
Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder [NCT02924090]Phase 448 participants (Anticipated)Interventional2016-09-30Recruiting
Comparative Effect of Etomidate and Propofol on Major Complications After Abdominal Surgery in Elderly Patients [NCT02910206]1,917 participants (Actual)Interventional2017-08-15Completed
Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial) [NCT05358535]Phase 3200 participants (Anticipated)Interventional2022-09-19Recruiting
the Effect of Single Dose of Etomidate Used During Emergency Intubation on Hemodynamics and Adrenal Cortex: a Randomized Clinical Trial [NCT01792037]Phase 490 participants (Actual)Interventional2012-12-31Completed
A Multicenter Open-label Randomized Controlled Clinical Trial of Etomidate Emulsion for Sedation in Patients Scheduled for Upper GI Endoscopy [NCT01729897]328 participants (Actual)Interventional2012-05-31Completed
Effect of an Anesthetic Induction Dose of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery [NCT00415701]Phase 4130 participants (Anticipated)Interventional2006-11-30Completed
Etomidate Versus Midazolam for Pre-Hospital Intubation: A Prospective, Randomized Trial [NCT00248729]Phase 20 participants Interventional2002-10-31Completed
A Single Dose of Etomidate During Rapid Sequence Induction in Trauma Patients Causes Significant Adrenocortical Insufficiency: A Prospective Randomized Study [NCT00462644]30 participants (Actual)Interventional2006-02-28Completed
Spontaneous and Oxytocin-induced Contractility After Exposure to Intravenous Anesthetic Agents: an In-vitro Study in Human Myometrium [NCT03852797]33 participants (Actual)Interventional2019-03-28Completed
Anesthesia for Upper Endoscopy and Colonoscopy in Cardiac Patients With Acute Anemia: Pretreatment With Low-dose Ketamine Can Reduce the Dose of Etomidate. A Randomized Clinical Trial. [NCT04857450]60 participants (Anticipated)Interventional2020-11-20Recruiting
Safety and Efficacy of Remazolam in Gastroenteroscopy in Elderly Patients [NCT05103696]120 participants (Actual)Interventional2021-10-01Completed
Characteristic Changes During Anesthesia With Etomidate and Propofol [NCT04369014]68 participants (Anticipated)Interventional2022-02-28Recruiting
Efficacy and Safety of Etomidate Combined With Propofol Intravenous Anesthesia During Hysteroscopic Procedures: a Randomized Controlled Trial [NCT05259787]Phase 4366 participants (Anticipated)Interventional2022-09-28Recruiting
Comparison of Etomidate Plus Propofol, Etomidate Alone on Induction of Anesthesia [NCT03820388]Phase 475 participants (Actual)Interventional2017-12-01Completed
"Ketamine / Propofol Admixture Ketofol at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial" [NCT02105415]Phase 2/Phase 3160 participants (Actual)Interventional2014-04-30Completed
The Effects of Spinal Anesthesia on ED50 and BIS50 of Etomidate for the Loss of Consciousness [NCT03240055]54 participants (Actual)Interventional2017-06-01Completed
Randomized Controlled Study of Etomidate Induction in Hysteroscopic Surgery [NCT05520645]200 participants (Anticipated)Interventional2022-08-25Not yet recruiting
Effects of Intravenous Lidocaine Infusion on Stress Response in Patients Undergoing Abdominal Surgery During Perioperative Anesthesia and Its Correlation With Serum Orphanin FQ (N/OFQ) [NCT05899127]Phase 480 participants (Anticipated)Interventional2023-07-22Recruiting
Ketamine Versus Etomidate for Sedation of Emergency Department Patients During Rapid Sequence Intubation [NCT01823328]Phase 4143 participants (Actual)Interventional2013-09-30Completed
Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus During General Anesthesia Induction Period [NCT02518789]Phase 4132 participants (Anticipated)Interventional2015-09-30Not yet recruiting
Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP) [NCT02027311]Phase 463 participants (Actual)Interventional2013-04-30Completed
Ulku Ozgul, Associate Professor, Inonu University, Department of Anesthesiology and Reanimation [NCT02500225]Phase 425 participants (Actual)Interventional2017-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00441792 (2) [back to overview]Length of Stay
NCT00441792 (2) [back to overview]Mortality
NCT00462644 (7) [back to overview]Change in Baseline Cortisol
NCT00462644 (7) [back to overview]Cortisol Level 60 Minutes After Cortisol Stimulating Test (CST)
NCT00462644 (7) [back to overview]Hospital Length of Stay
NCT00462644 (7) [back to overview]Intensive Care Unit (ICU) Length of Stay
NCT00462644 (7) [back to overview]Number of Deaths
NCT00462644 (7) [back to overview]Postintubation Cortisol (Baseline Cortisol Level)
NCT00462644 (7) [back to overview]Ventilator Days
NCT01823328 (8) [back to overview]Doses of Post-intubation Sedation
NCT01823328 (8) [back to overview]SOFA Score
NCT01823328 (8) [back to overview]Peak and Plateau Pressure
NCT01823328 (8) [back to overview]Number of Patients With Post-intubation Hypoxemia
NCT01823328 (8) [back to overview]Number of Patients With Hypotension
NCT01823328 (8) [back to overview]Number of Patients With First-pass Success
NCT01823328 (8) [back to overview]Mortality in Sepsis and Septic Shock
NCT01823328 (8) [back to overview]Mortality
NCT02027311 (2) [back to overview]Event of Hypoxia
NCT02027311 (2) [back to overview]Number of Intervention
NCT02105415 (8) [back to overview]Mean Arterial Pressure
NCT02105415 (8) [back to overview]Vasopressor Use
NCT02105415 (8) [back to overview]Mechanical Ventilation Free Days
NCT02105415 (8) [back to overview]Intensive Care Unit Free Days
NCT02105415 (8) [back to overview]Mortality
NCT02105415 (8) [back to overview]Number of Participants Experiencing Delirium Using Confusion Assessment Method in ICU
NCT02105415 (8) [back to overview]Number of Participants With Adrenal Insufficiency
NCT02105415 (8) [back to overview]Blood Product Transfusions
NCT02643381 (7) [back to overview]Duration of Mechanical Ventilation
NCT02643381 (7) [back to overview]Length of Stay in ICU
NCT02643381 (7) [back to overview]Survival at Day 7
NCT02643381 (7) [back to overview]Duration of Catecholamine Therapy
NCT02643381 (7) [back to overview]Sequential Organ Failure Assessment (SOFA) Scores
NCT02643381 (7) [back to overview]Survival at Day 28
NCT02643381 (7) [back to overview]Number of Participants With New Diagnosis of Adrenal Insufficiency
NCT03545503 (1) [back to overview]Hemodynamic Effect as Measured by Systolic Blood Pressure Before and After RSI
NCT03820388 (8) [back to overview]Pain at Injection Site
NCT03820388 (8) [back to overview]Myoclonic Movements
NCT03820388 (8) [back to overview]Post-operative Nausea and Vomiting
NCT03820388 (8) [back to overview]Intubation Time
NCT03820388 (8) [back to overview]Heart Rate
NCT03820388 (8) [back to overview]Eyelash Reflex Disappear Time
NCT03820388 (8) [back to overview]Blood Pressure
NCT03820388 (8) [back to overview]Sedation Depth

Length of Stay

The primary outcome of the study was hospital length of stay. (NCT00441792)
Timeframe: time in days of hospitalization

Interventiondays (Median)
Midazolam9.5
Etomidate7.3

[back to top]

Mortality

In-hospital mortality. (NCT00441792)
Timeframe: Duration of hospitalization.

Interventionpercentage of patients dying (Number)
Midazolam36
Etomidate43

[back to top]

Change in Baseline Cortisol

change from baseline cortisol (drawn prior to RSI) to 2nd cortisol level (4-6hrs after RSI, but before stim test) (NCT00462644)
Timeframe: 4-6hr after RSI

Interventionmicrograms/dL (Mean)
Etomidate-12.8
Fentanyl-Midazolam1.1

[back to top]

Cortisol Level 60 Minutes After Cortisol Stimulating Test (CST)

(NCT00462644)
Timeframe: 60 minutes after administration of cotrosyn

Interventionmicrograms/dL (Mean)
Etomidate22.91
Fentanyl-Midazolam39.09

[back to top]

Hospital Length of Stay

days from admission to hospital discharge (NCT00462644)
Timeframe: time to hospital discharge in days

Interventiondays (Mean)
Etomidate13.9
Fentanyl-Midazolam6.4

[back to top]

Intensive Care Unit (ICU) Length of Stay

ICU length of stay in days (NCT00462644)
Timeframe: time from hospital admission to transfer out of ICU to floor bed

Interventiondays (Mean)
Etomidate8.1
Fentanyl-Midazolam3.0

[back to top]

Number of Deaths

deaths (NCT00462644)
Timeframe: death in hospital

Interventionparticipants (Number)
Etomidate2
Fentanyl-Midazolam0

[back to top]

Postintubation Cortisol (Baseline Cortisol Level)

cortisol level after randomization and rapid sequence induction (NCT00462644)
Timeframe: postintubation (baseline cortisol level)

Interventionmicrograms/dL (Mean)
Etomidate18.2
Fentanyl-Midazolam27.9

[back to top]

Ventilator Days

(NCT00462644)
Timeframe: time from intubation to extubation

Interventiondays (Mean)
Etomidate6.3
Fentanyl-Midazolam1.5

[back to top]

Doses of Post-intubation Sedation

The number of bolus doses of sedative administered post-intubation will be compared up to 6 hours (including morphine, dexmedetomidine, propofol , etomidate, ketamine, lorazepam (Ativan), midazolam (Versed), diazepam (Valium), fentanyl, hydromorphone (Dilaudid)). Infusions of these medications will be recorded separately but will not be part of this outcome. (NCT01823328)
Timeframe: up to 6 hours

Interventionbolus doses of sedation (Median)
Ketamine1
Etomidate1

[back to top]

SOFA Score

*Maximum SOFA score within three hospital days: all patients. SOFA score is the Sequential Organ Failure Assessment. The minimum score is 0, the maximum score is 24, with higher scores indicating higher likelihood of worse outcome. (NCT01823328)
Timeframe: up to 3 days

Interventionunits on a scale (Median)
Ketamine6.5
Etomidate7

[back to top]

Peak and Plateau Pressure

The Peak and plateau pressures will be compared between the two groups, with a pre-defined subgroup analysis of patients who are being intubated for severe asthma and chronic obstructive pulmonary disease (COPD). The ventilator was used to measure these values. (NCT01823328)
Timeframe: up to 30 minutes (average time frame)

,
Interventioncm water (Median)
Peak pressurePlateau Pressure
Etomidate2617
Ketamine2516

[back to top]

Number of Patients With Post-intubation Hypoxemia

"The following will be compared between the two groups:~Hypoxemia and severe hypoxemia in the peri-intubation period. Peri-intubation hypoxemia was defined as during after the 5 minutes immediately after intubation.~Hypoxemia within the first 2 hours intubation~Hypoxemia is defined as SpO2 less than 90%. Severe hypoxemia is defined as SpO2 less than 90% for 60 seconds or more." (NCT01823328)
Timeframe: up to 2 hours

,
InterventionParticipants (Count of Participants)
Peri-intubation hypoxemiaHypoxemia within 2 h of ICU admission
Etomidate135
Ketamine81

[back to top]

Number of Patients With Hypotension

"The following will be compared between the two groups:~Hypotension in the ED post-intubation~Hypotension within the first 6 hours of the hospital stay, including time spent in the ED~Hypotension is defined as a systolic blood pressure less than 90 mm Hg" (NCT01823328)
Timeframe: up to 6 hours

,
InterventionParticipants (Count of Participants)
Hypotension in the first 6 hours of hospitalizatioHypotension in the ED
Etomidate3017
Ketamine2416

[back to top]

Number of Patients With First-pass Success

The rate of first pass success, defined as successful tracheal intubation on the first attempt. An attempt is defined as the insertion and subsequent removal of the laryngoscopic device from the patient's mouth, regardless of whether an endotracheal tube was inserted. (NCT01823328)
Timeframe: up to 5 minutes (average time frame)

InterventionParticipants (Count of Participants)
Ketamine59
Etomidate60

[back to top]

Mortality in Sepsis and Septic Shock

"Evaluate mortality for the sub-group diagnosed with sepsis and septic shock, defined as:~- Suspected infection, and at least 2 of 4 systemic inflammatory response syndrome (SIRS) criteria:~Temperature >38C or <36C~Respiratory Rate >20 or PaCO2 <32 mmHg~Heart Rate >90~White blood cell count >12,000 or <4,000, or > 10% bands~Septic shock:~defined as sepsis plus either: 1) Systolic blood pressure <90 after 1L of intravenous fluid or 2) lactate >=4mmol/L" (NCT01823328)
Timeframe: 30 Days

InterventionParticipants (Count of Participants)
Ketamine1
Etomidate4

[back to top]

Mortality

Mortality will be assessed at 30 days or at discharge from the hospital, whichever occurs first. This study is not powered to detect a significant difference in mortality, however; this will primarily be a safety study comparing the use ketamine versus etomidate as sedative agents for rapid sequence intubation (RSI) in the Emergency Department (ED). (NCT01823328)
Timeframe: 30 Days or Discharge

InterventionParticipants (Count of Participants)
Ketamine8
Etomidate15

[back to top]

Event of Hypoxia

Hypoxia defined as peripheral blood oxygen saturation measured by pulse oxymeter < 90% (NCT02027311)
Timeframe: Every 5min in Preoperative, intraoperative phase and 15 min in Recovery phase

InterventionHypoxia events (Number)
Midazolam19
Etomidate27

[back to top]

Number of Intervention

The frequency of intervention which was defined as any restraint of the patient's head, arms, or legs if they became agitated, or if patient movement was not controlled with verbal instruction from the endoscopist during the whole intraoperative phases. (NCT02027311)
Timeframe: Throughout the whole ERCP procedure

InterventionNumber of intervention (Mean)
Etomidate1.9
Midazolam7.5

[back to top]

Mean Arterial Pressure

Mean arterial pressure for the ketamine/propofol group at a 1:1 dose ratio compared to the etomidate group within the first 15 minutes post-administration in patients in need of urgent and/or emergent endotracheal intubation, as defined by any intubation within the intensive care unit excluding intubations for elective procedural events and codes. (NCT02105415)
Timeframe: baseline and every 5 minutes up to 15 minutes minutes post study drug administration

,
Interventionmm Hg (Mean)
Baseline5 minutes10 minutes15 minutes
Etomidate82.881.781.979.1
Ketamine / Propofol Admixture80.977.675.375.5

[back to top]

Vasopressor Use

The use of vasoactive medications to restore the blood pressure post-administration in the ketamine/propofol combination as compared to the etomidate group. (NCT02105415)
Timeframe: up to 24 hours post study drug administration

,
InterventionParticipants (Count of Participants)
Pre-treamentNew-onset pressors (within 3 minutes)Delayed-onset pressors (within 24 hours)
Etomidate11257
Ketamine / Propofol Admixture51864

[back to top]

Mechanical Ventilation Free Days

comparison of mechanical ventilation free days between the two groups (NCT02105415)
Timeframe: hospital discharge or day 28, whichever comes first

Interventiondays (Median)
Etomidate22
Ketamine / Propofol Admixture20

[back to top]

Intensive Care Unit Free Days

comparison of intensive care unit free days between the two groups (NCT02105415)
Timeframe: hospital discharge or day 28, whichever comes first

Interventiondays (Median)
Etomidate16
Ketamine / Propofol Admixture17

[back to top]

Mortality

In-hospital/28 day mortality among patients in ketamine/propofol combination compared to in-hospital/28-day mortality in etomidate. (NCT02105415)
Timeframe: Hospital Discharge or Day 28, whichever comes first

InterventionParticipants (Count of Participants)
Etomidate26
Ketamine / Propofol Admixture25

[back to top]

Number of Participants Experiencing Delirium Using Confusion Assessment Method in ICU

Comparison of number of participants who were positive for delirium using CAM-ICU between groups (NCT02105415)
Timeframe: up to 24 hours post study drug administration

InterventionParticipants (Count of Participants)
Etomidate7
Ketamine / Propofol Admixture4

[back to top]

Number of Participants With Adrenal Insufficiency

Incidence of adrenal insufficiency between ketamine/propofol admixture and etomidate. Adrenal insuffiency was evaluated with co-syntropin stimulation test. (NCT02105415)
Timeframe: up to 24 hours post study drug administration

InterventionParticipants (Count of Participants)
Etomidate (3-5 Hours)13
Ketamine/Propofol Admixture (3-5 Hours)5
Etomidate (23-25 Hours)9
Ketamine/Propofol Admixture (23-25 Hours)6

[back to top]

Blood Product Transfusions

blood product transfusions [Red Blood Cells vs. non-Red Blood Cells] between the two groups (NCT02105415)
Timeframe: hospital discharge or day 28, whichever comes first

,
InterventionParticipants (Count of Participants)
Red blood cellNon-red blood cellColloid
Etomidate211628
Ketamine / Propofol Admixture13826

[back to top]

Duration of Mechanical Ventilation

Duration (in days) from insertion to removal of mechanical ventilation (NCT02643381)
Timeframe: From time of documented insertion until the time of documented removal, assessed up to 28 days

InterventionDays (Median)
Etomidate5
Ketamine5

[back to top]

Length of Stay in ICU

Length (in days) of ICU stay (NCT02643381)
Timeframe: Assessed up to 28 days

InterventionDays (Median)
Etomidate8
Ketamine9

[back to top]

Survival at Day 7

Survival is defined as the number of participants survived at day 7 following emergency endotracheal intubation (NCT02643381)
Timeframe: Day 7

InterventionParticipants (Count of Participants)
Etomidate306
Ketamine336

[back to top]

Duration of Catecholamine Therapy

Time (in days) from start to end of catecholamine therapy (NCT02643381)
Timeframe: From time of documented start of therapy until the time of documented end of therapy, assessed up to 28 days

InterventionDays (Median)
Etomidate1
Ketamine1

[back to top]

Sequential Organ Failure Assessment (SOFA) Scores

Sequential Organ Failure Assessment (SOFA) is a scoring system that assesses the performance of several organ systems. Possible scores range from 0 to 24. Higher score indicates higher degree of organ dysfunction (NCT02643381)
Timeframe: Day 1, Day 2, Day 3, Day 4

,
Interventionscore on a scale (Mean)
Day 1Day 2Day 3Day 4
Etomidate10.79.88.47.4
Ketamine10.99.58.47.4

[back to top]

Survival at Day 28

Survival is defined as the number of participants survived at day 28 following emergency endotracheal intubation (NCT02643381)
Timeframe: Day 28

InterventionParticipants (Count of Participants)
Etomidate254
Ketamine264

[back to top]

Number of Participants With New Diagnosis of Adrenal Insufficiency

New diagnosis of adrenal insufficiency will be assessed by the the primary treating medical or surgical team via chart review (NCT02643381)
Timeframe: Day 28

InterventionParticipants (Count of Participants)
Etomidate11
Ketamine4

[back to top]

Hemodynamic Effect as Measured by Systolic Blood Pressure Before and After RSI

The primary outcome of this study is to determine the change in hemodynamic response comparing systolic blood pressure pre-versus post-administration of study drug. A significant hemodynamic response is defined as a decrease in systolic blood pressure of 20% or greater between the pre versus post administered study drug. (NCT03545503)
Timeframe: The hemodynamic response will be measured by assessing the change in vital signs between 15 minutes prior to administration and vitals up to 15 minutes after the administration of the study drug.

,
InterventionmmHg (Mean)
Pre-SBPPost SBP 0-7Post SBP 8-15
Etomidate138.04139.09130.42
Ketamine132.39130.09120.80

[back to top]

Pain at Injection Site

Pain on injection will be measured using 4 graded scale; 0 = no pain, 1 = verbal complaint of pain, 2 = withdrawal of arm, 3 = both verbal complaint and withdrawal of arm. (NCT03820388)
Timeframe: intraoperative

InterventionParticipants (Count of Participants)
Propofol Group7
Etomidate Group0
Propofol Plus Etomidate Group0

[back to top]

Myoclonic Movements

The incidence and degree of myoclonic movements also recorded as follows: 0 = no myoclonic movements, 1 = minor myoclonic movements, 2 = moderate myoclonic movements, 3 = major myoclonic movements. (NCT03820388)
Timeframe: intraoperative

InterventionParticipants (Count of Participants)
Propofol Group1
Etomidate Group6
Propofol Plus Etomidate Group1

[back to top]

Post-operative Nausea and Vomiting

Presence of post-operative nausea or vomiting (yes/no). (NCT03820388)
Timeframe: 24 hours post-operation

InterventionParticipants (Count of Participants)
Propofol Group0
Etomidate Group1
Propofol Plus Etomidate Group2

[back to top]

Intubation Time

Duration of orotracheal intubation. (NCT03820388)
Timeframe: Up to 2 hours

Interventionminutes (Mean)
Propofol Group92
Etomidate Group95
Propofol Plus Etomidate Group93

[back to top]

Heart Rate

Heart Rate changes during induction (Beats Per min) (NCT03820388)
Timeframe: 10 minutes after induction (intraoperative)

Interventionbpm (Mean)
Propofol Group77
Etomidate Group74
Propofol Plus Etomidate Group74

[back to top]

Eyelash Reflex Disappear Time

Time to disappearance of eyelash reflex after induction. (NCT03820388)
Timeframe: Post induction, up to 1 hour

Interventionminutes (Mean)
Propofol Group31.9
Etomidate Group34.5
Propofol Plus Etomidate Group32.4

[back to top]

Blood Pressure

Blood Pressure Fluctuations during Induction; change of blood pressure from baseline from induction to 10 min after induction. (NCT03820388)
Timeframe: 10 minutes after induction (intraoperative)

InterventionmmHg (Mean)
Propofol Group105
Etomidate Group122
Propofol Plus Etomidate Group117.88

[back to top]

Sedation Depth

Sedation depth using bispectral index (BIS). BIS scores range from 0-100. A value of 0 indicates no EEG activity, 40-60 indicates an appropriate level of general anesthesia, and 90-100 is typical of a state of wakefulness. (NCT03820388)
Timeframe: 30 minutes post-induction

Interventionunits on a scale (Mean)
Propofol Group30
Etomidate Group38
Propofol Plus Etomidate Group38

[back to top]